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 SUMMARY 
 
 
Introduction. Hepatocellular Carcinoma (HCC) ranks fifth in frequency of cancers in the 
world. Orthotopic Liver Transplantation (OLT) or liver resection represents the best 
treatments for HCC. However, most patients cannot be subjected to potential curative OLT or 
resection because of extensive tumor involvement of the liver, metastasis, invasion of the 
portal vein or advanced underlying hepatocellular disease at the time of diagnosis. Systemic 
chemotherapy or chemoembolization represent a good alternative for the treatment, however 
drug therapy of cancer in general is hampered by multidrug resistance (MDR) that is a 
phenomenon caused by the up-regulation of the ABC-transporters (ABC) leading to 
chemotherapy failure. 
To overcome these problems new therapeutic approaches, such gene therapy, are needed. 
Selective down-regulation of an essential and specific cancer gene such as telomerase 
(hTERT) could represent an emerging strategy that could prevent cancer progression and 
diminish numerous side effects derived from drug usage. 
The present study include two tasks whose aims are: 
Task 1: a) Assess if the extent of tumoral differentiation results in a different ABCB1, 
ABCC1 and ABCG2 expression. 
b) Assess whether the treatment with a chemotherapeutic drug(s) may affect the 
expression of the three ABC transporters under study. 
Task 2:  to overcome the obstacle of MDR-induced chemoresistance using new therapeutic 
approaches such as gene therapy, silencing a cancer essential and specific gene. 
Results and discussion. Task 1: We assessed the ABCB1, ABCC1 and ABCG2 expression 
in three hepatic cell lines: IHH (non tumoral control), HuH7 (differentiated tumoral cells) and 
JHH6 (undifferentiated tumoral cells). Only ABCG2 expression correlates with the degree of 
tumoral differentiation. 
Through confocal microscopy analysis we observed that the Doxorubicin (Dox) is able to 
reach the cell’s nucleus within 10 min. After 24h and 48h Dox is completely concentrated into 
the nucleus where some nuclear damage occurs. The presence of damaged nuclei could 
explain the decreased mRNA in most of the ABCs under study. The treatment with Dox doses 
lower than the LC50 for 24h and 48h has different consequences for all the ABC considered in 
the three cell lines, with an mRNA expression pattern not in line with the protein one in most 
of the cases, suggesting that the possible mechanism that determines the ABCs protein 
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upregulation in the  tumoral cell lines (Huh7 and JHH6) is not the de-novo transcription but 
probably something related to the protein turnover. 
After the treatment ABCC1 protein expression increases in the tumoral cell lines but not in 
the non tumoral one (IHH). Regarding ABCB1 and ABCG2, these transporters seem to play a 
role only in Huh7 and JHH6 cells respectively. We were not able to correlate the tumorigenic 
potential of the two tumoral cell lines with the ABC expression since the different behaviour 
of ABCs and the different contribution to MDR. Thus in order to better clarify the 
contribution of each single ABC to MDR our future steps will consider the use specific 
inhibitors. 
Task 2: From our in vivo data, among four cancer related genes we selected hTERT as the 
best candidate for silencing experiments due to its exclusive expression in tumoral samples. A 
functional non-inflammatory siRNA targeting hTERT was designed: SirTel 1. 
Silencing experiments were conducted in JHH6 cell line. The hTERT silencing effect was 
dose dependent, at least at the three considered doses (25-50-100nM). For all the subsequent 
determinations the experimental concentration was 25nM. After 72h of silencing we observed 
a significant reduction in both hTERT mRNA expression and enzymatic activity (p<0.001). 
The effects observed in the cells after silencing are: 
- morphological changes, from a fibroblast-like to an hepatocyte-like shape; 
- increased albumin expression. The expression of this  hepatic hallmark increases after 
silencing in JHH6 cells that, due to their poor degree of differentiation, at basal 
conditions do not express quantifiable levels of albumin. The peak of the higher 
albumin expression corresponds to the maximum hTERT silencing effect. 
- decreased cell viability (p<0.01). Interestingly, the siRNA induced a reduction in cell 
viability higher than Dox.  
- cell cycle arrest in G1 phase (p<0.01) 
All data were validated using a hTERT negative cell line (primary culture of human 
fibroblast). 
After 72h silencing, we observed that hTERT expression reaches its minimum, and the 
expression is recovered after 264h although it does not reach the initial expression levels. Re-
exposing the cells to additional 25nM of siRNA induces a reduction of mRNA levels by 76% 
compared to the amount already present after the first treatment. 
Taken together all this results suggest the pivotal role of hTERT silencing in a HCC derived 
cell line. Therefore, hTERT represent a promising candidate for gene-therapy strategies in 
HCC.
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TASK 1. MULTIDRUG RESISTANCE IN HEPATOCELLULAR CARCINOMA 
 
 
Hepatocellular Carcinoma  
 
Hepatocellular Carcinoma 
(HCC) is the third most 
common cause of cancer death 
worldwide counting 700,000 
death per year. The presence of 
several relevant risk factors 
such as HCV and HBV 
infections, alcoholic cirrhosis 
and non-alcoholic steato-
hepatitis explains the geogra-
phic distribution of liver cancer 
with the majority of cases seen 
in the developing countries where the HCV and HBV infections are common [1] (Fig.1). 
The HCC presents as nodular, multinodular or with an infiltrative growth pattern. Tumor 
nodules are round to oval, grey or green (if the tumor produces bile), well circumscribed but 
not encapsulated. The diffuse type is poorly circumscribed and infiltrates the portal vein, or 
more rarely the hepatic veins [2] (Fig. 2). 
The carcinogenesis remains still unclear although it has 
been hypothesized that chronic diseases, continuous cell 
proliferation and direct oncogenic action of 
viruses/toxins lead genomic instability that enhances the 
rate of genomic alteration required for cellular 
transformation (loss of tumor suppressors, de-repression 
of oncogenes). Despite considerable progress in HCC 
treatment, the overall prognosis is still not good, since 
majority of the patients are identified with an advanced 
Figure 1. Estimated crude incidence rate per 100,000 habitants, both sexes, 
all ages.  
 
Figure 2. HCC, 10x magnification, 
hematoxylin-eosin stain. 
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disease, consequently that preventing potentially curative treatments [3]. Surveillance with 
abdominal ultrasound (US) of patients at risk, is an end-point that is achieved in a minority of 
patients, especially in the developed world [4]. American Association for the Study of the 
Liver Diseases (AASLD), European Association for the Study of the Liver (EASL) and Asia 
Pacific Association for the Study of the Liver (APASL) share common guidelines for 
semestral surveillance with abdominal US of all patients at risk [4-6], as the growth rate of the 
tumor takes 6 months to double its volume, on average [4]. The co-existence of multiple 
diseases in the HCC have substantial influence on the choice of therapy and survival. The 
guide lines for the treatment of HCC are provided by the Barcelona Clinic Liver Cancer 
(BCLC) staging system that suggests curative treatments such as resection or Orthopic Liver 
Transplantation (OLT) for the lower stages. Drug based palliative treatments are 
recommended for the intermediated stages while for the higher grade tumours a symptomatic 
treatment represent the only option available [7] (Fig. 3).  
 
 Figure 3. Barcelona Clinic Liver Cancer (BCLC) Staging and Treatment Strategy scheme. 
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Late diagnosis, stage, severity of the underlying liver disease and the lack of liver donors are 
responsible for the poor outcome of the HCC. Liver Resection (LR) is still the treatment of 
choice for early-stage HCC with well-preserved liver function; surgery provides good long-
term survival but can be applied in only to 20–30% of patients with HCC on cirrhosis [8]. 
Several cohort studies comparing LR and loco-regional ablation treatment (LAT) for patients 
affected by HCC on cirrhosis have been published in literature, however the results of these 
studies are often conflicting and are affected by the heterogeneity of selection and patient 
management [9,10]. Moreover, two recent randomized trials failed to clarify the role of LAT 
and LR; the first [11] of the two studies showed that survival rates in patients with early HCC 
(single, ≤5 cm) were similar after LAT and LR, and the second [12] demonstrated the 
superiority of LR also in small HCC (single, ≤3 cm). 
Same observational studies [12] have found that in small HCC (4 or 5 cm), survival and 
disease-free survival are comparable between surgery and LAT, other recently published RCT 
comparing 115 patients within Milan criteria showed the superiority of LR in both survival 
and disease-free survival; these results were confirmed also in single and small HCCs [11]. 
 
 
HCC and chemoresistance: The role of ABC transporters 
 
Although LR or OLT represent the eligible choice for HCC treatment, most patients cannot be 
subjected to these potential curative therapies because of extensive tumor involvement of the 
liver, metastasis, invasion of the portal vein or advanced underlying hepatocellular disease at 
the time of diagnosis. Systemic chemotherapy or chemoembolization represent a valuable 
alternative for the treatment, however drug therapy of cancer in general is hampered by 
multidrug resistance (MDR) [13-15]. MDR is the phenomenon in which cancer cells exposed 
to one anticancer drug show resistance to various antitumoral agents that are structurally and 
functionally different from the initial one.  
MDR is a multifactorial process since up to now no single mechanism has been identified 
accounting for resistance to the entire spectrum of anticancer drugs commonly used, however 
after the identification of the first ATP binding cassette (ABC) protein [16], was demonstrated 
that a single protein could confer resistance to a wide range of chemical compounds [17]. 
Mechanisms involved in MDR are activation of the drug efflux systems, phase I and II 
enzymes, alterations of the genes and the proteins involved into the control of apoptosis, 
absorption, metabolism and delivery, DNA methylation. 
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Soon after the introduction of chemotherapy in 1950s it was observed that cancer cells could 
became resistant to cytotoxic drugs [18]. During the next thirty years the primary role of ABC 
transporters in MDR was established [16,19,20] and during this period became evident the 
association between ABC overexpression and HCC resistance in animal models [21,22].  
 
 
ABC transporters  
 
ABC transporters are large membrane-bound proteins that use energy to drive the transport of 
various molecules across the plasma membrane as well as intracellular membranes of the ER, 
peroxisome and mitochondria [23,24]. They are present in practically all living organisms 
from prokaryotes to mammals [24]. ABC transporters are expressed basically in all tissues, 
with differential subcellular localization; in polarized cells they can be expressed in apical or 
basolateral membranes [25-27]. 
The ABC family comprehend 49 genes wich are widely dispersed in the genome. Based on 
similarity in gene structure in eukaryotes ABCs can be divided into seven subfamilies named 
from A to G in where every member is numbered consequently [25,28].  
In humans, the three major types of multidrug resistance (MDR) proteins include members of 
the ABCB (ABCB1/MDR1/P-glycoprotein), the ABCC (ABCC1/MRP1, ABCC2/MRP2, 
probably also ABCC3-6, and ABCC10-11), and ABCG (ABCG2/MXR/BCRP) subfamily 
[27].  
Functional ABC transporters 
contain two membrane-spanning 
domains (MSDs) (from 5 to 10 
elices, tipically 6) and two 
nucleotide binding domains 
(NBDs) [24]. They can be 
encoded in a single polypeptide in 
a order NH2-MSD-NBD-MSD-
NBD-COOH (Fig.4) or can be 
homo- or heterodimer following the 
order NH2-MSD-NBD-COOH that 
sometimes could be reversed as in ABCG2 [29]. The ABC unit harbours several conserved 
sequence motifs: the Walker A (P-loop), a glycine-rich sequence; the Walker B motif; both 
The figure illustrates a probable topology of a single chain encoded ABC. 
In blue and green are evidenced the two transmembrane domains (MSD). 
In red and yellow the Walker A and B domains respectively. In orange 
the “C” motif. 
Figure 4. Example topology of an ABCC transporter. 
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involved in ATP binding and hydrolysis [30]; and a conserved glutamine (Q-loop) also 
known as C signature or C motif, which is characteristic of ABC ATPases and the has the 
core motif LSGGQ [31]. 
ABC pumps are mostly unidirectional, in bacteria they principally import essential 
compounds into the cell, in eukaryotes they move compounds from cytoplasm to the 
extracellular compartment or into cellular organelles: ER, mitochondria, peroxisome. 
This transporters use ATP hydrolysis derived energy to move the substrate. 
The transport across the membrane involve a cyclic process which starts with the transporter 
in a “open” state with two ATP molecules loosely bound to the NBDs. The substrate binding 
to a high affinity site(s) induces conformational changes that enhance the ATP binding to 
NBD1. The initial binding of ATP by NBD1 stabilizes the interaction between NBDs by 
establishing contacts with the C signature of NBD2, facilitating the binding of a second 
Figure 5: Subcellular localization and substrate specificity of some ABC transporters. 
The cartoon shows two polarized cells. The subcellular location(s) of each protein on the apical (upper) or basolateral 
membranes is shown. Some of the major classes of substrates for each protein are indicated, as well as specific examples of 
substrates chosen to illustrate the overlap in substrate profiles among the ABCs.  
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molecule of ATP. The ATP binding induces a tighter interaction between the NBDs which 
transfer the movement to the MSDs resulting in a decrease in the substrate affinity [27,32]. At 
this stage only one ATP is tightly bound and hydrolyzed, Senior and Coll. [33] suggest that 
the binding of one ATP molecule at NBD1 promotes the hydrolysis of the ATP molecule at 
NBD2. The hydrolyzation is a multistep process which ends with a phosphate release [33]. 
This step can be blocked by phosphate-mimicking molecules, such as vanadate, that stabilize 
the complex ADP:Vi:protein [33]. After the ADP release the protein is ready for another cycle 
with the ATP hydrolysis occurring in the other NBD since the NBDs are functionally 
equivalent. The fact that the NBDs can be exchanged without loss of function provides strong 
support for this cycling model [34]. Although the ATPase activity is required for transport 
and substrate increase the rate of ATP hydrolysis, it is not know which steps are associated 
with binding, transport and release of substrate [35]. In the case ABCB1, considerable 
evidence exists to support a model in which hydrolysis of ATP at either NBS results in 
transport of one molecule of substrate [33]. A more recent variation of this model proposes 
that the binding and hydrolysis of one ATP molecule drives a “power stroke” in which the 
protein shifts from a high- to low-affinity substrate binding state with the concomitant 
transport and release of one molecule of substrate [35]. Hydrolysis of a second ATP is then 
required to reset the protein in a high-affinity state for the next transport cycle.  
In contrast with these studies some researchers sustain that it is ATP binding rather than 
hydrolysis that converts the protein from a high- to low-affinity substrate binding state 
[36,37]. 
Mutational studies have also identified individual amino acids that are important for the 
transport of a range of diverse substrates [38,39]. Substrates establish multiple, often but not 
always, overlapping interactions with amino acid residues that collectively form a relatively 
large binding pocket, as a consequence a single amino acid mutation can alter transport of 
some substrates and not others [40-43]. In ABCCs TM11 and TM17 and in ABCB1 TM6 and 
TM12 play major roles in determining its substrate specificity. Moreover mutational studies 
of TM17 in ABCC1 ABCC2 and ABCC3 have revealed multiple polar and/or aromatic 
residues and basic residues that have pronounced effects on substrate specificity, with respect 
to various classes of natural product drugs and conjugated organic anions, such as E217_G 
and LTC4 (Leukotriene C4), as well as folic acid analogs such as methotrexate and leucovorin 
[44-48]. 
One of the most striking examples of a major alteration in substrate specificity resulting from 
single amino acid variation came from the functional characterization of mammalian ABCC1 
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orthologs. ABCC1 is relatively highly conserved among mammals, and the human protein 
exhibits 88, 86, 92, and 98% sequence identity with the mouse, rat, dog, and macaque 
proteins, respectively [49-52]. However, with the exception of macaque ABCC1, the other 
orthologs fail to confer resistance to anthracyclines and are poor transporters of E217_G [49-
51,53]. The lack of anthracycline resistance has been traced to the presence of a Gln rather 
than Glu residue in TM14 (Glu1086 in human ABCC1), while the poor E217_G transport 
seems attributable in large part to the presence of Ala rather than Thr in TM17 (Thr1242 in 
human ABCC1) [54,55].  
Finally should be noted that several residues have been identified that, rather than being 
important for the activity or substrate specificity of some ABC, such as ABCC1 for example, 
play a critical role in the stable expression of the transporter in mammalian cell plasma 
membranes [42,43,56]. 
ABC proteins have a relevant role in the transport of both endo- and xenobiotics [25].  
Each ABC has a broad overlapping substrate spectrum which encompasses GST-, 
glucuronide- and sulphate- conjugates [57-59], nucleotide or nucleoside analogous such as 
cAMP, cGMP, 5’-fluorouracil [60], GSH, GSSG [61], bile salts [62], steroids, prostaglandins 
and drugs, such as cisplatin and anthracyclines [25] (Fig. 5). 
In addition of the broad substrate specificity there are growing number of examples of 
compounds that bind to ABCs without being transported and many of these act as 
competitors. Of interest would be interesting could be the role of dietary flavonoids such as 
genistein or quercitin, as well as synthetic flavonoids, such as flavopiridol in the inhibition of 
ABCC1 and ABCC2; that could influence the drug ADME-tox (absorption, distribution, 
metabolism, excretion and toxicity) during therapies [63-65]. 
In addition there has been considerable interest in developing novel compounds that may 
prevent or reverse clinical MDR [66] such as the quinolone derivative MS-209, ABCB1 and 
ABCC1 inhibitor [67]; the pipecolinate derivative VX-710 (biricodar), ABCB1, ABCC1 and 
ABCG2 inhibitor [68]; and pyrrolpyrimidine analogs, ABCC1 specifics inhibitors [69]. 
Most of the trials of ABC reversing agents have had disappointing results [70-74], the 
explanation is that each ABC has a broad spectrum of substrate with an overlapping 
specificity as a consequence the role of a inhibited ABC can be supplied by an alternative 
transporter and this leads to a difficult interpretation of patients’ outcome. Furthermore, 
earlier ABCB1 reversing agents were of relatively low specificity and affinity and in some 
cases were found to have significant pharmacokinetic effects that required reduction in dosing 
of the chemotherapeutic agent(s) used. The second generation of ABCB1 reversing agents, 
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such as PSC833 (a nonimmunosuppressive derivative of cyclosporine), showed a role also in 
hepatic ABCC2, ABCB11, a bile salt transporter, and CYP3A modulation that could 
influence pharmacokinetics [74,75]. More recently, high-affinity highly specific, ABCB1 
specific reversing agents have been developed. One of these, zosuquidar (LY335979), has 
shown minimal pharmacokinetic effects, combined with confirmed inhibition of ABCB1 in 
recent phase I trials involving solid and hematological malignancies [76-78]. At present the 
outcomes of phase II trials of zosuquidar are not so promising. A randomized, placebo-
controlled, double-blind phase II study on metastatic breast cancer patient revealed that there 
was no difference in progression-free survival, overall survival, or response in patients treated 
with anticancer drug plus placebo and anticancer drug plus zosuquidar 3HCl (DZ) [79]. 
Dozens trials have been performed in the last twenty years and among these very few showed 
an increased overall survival in patients [26] and this is the reason why ABCs still remain a 
open field of investigation. 
Alternative approaches to target MDR come from peptides analogues, antibodies, efflux 
evading drugs, gene downregulation [26]. 
ABCB1 mediated drug resistance can be reversed by hydrophobic peptides that are high-
affinity ABCB1 substrates. Such peptides, showing high specificity to ABCB1, could 
represent a new class of compounds for consideration as potential chemosensitizers [80]. 
Peptide analogues of TMDs are believed to interfere with the proper assembly or function of 
the target protein and they can be specific and potent ABCs inhibitors as demonstrated for 
ABCB1 [81]. Studies suggest that immunization could be an alternative supplement to 
chemotherapy. A mouse monoclonal antibody directed against extracellular epitopes of 
ABCB1 was shown to inhibit the in vitro efflux of drug substrates [82]. Similarly, 
immunization of mice with external sequences of the murine gene abcb1 elicited antibodies 
capable of reverting the MDR phenotype in vitro and in vivo, without eliciting an autoimmune 
response [83]. 
The epothilones represent a novel class of anticancer therapy that stabilizes microtubules, 
causing cell death and tumor regression in preclinical models. They are not recognized by 
ABCs, providing proof of the concept that new classes of anticancer agents that do not 
interact with the multidrug transporters can be developed to improve response to therapy [84]. 
Selective downregulation of resistance genes in cancer cells is an emerging approach in 
therapeutics. Using peptide combinatorial libraries, Bartsevich and Coll. [85] designed 
transcriptional repressors that selectively bind to the ABCB1 resulting in a selective reduction 
in protein levels and a marked increase in chemosensitivity in highly drug-resistant cancer 
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[85,86]. Similarly, interference technologies could be a promising new strategy that is not 
only highly specific but also could prevent ABCs expression during disease progression. 
However, at present antisense oligonucleotides has produced mixed results; in certain cases 
sufficient downregulation of ABCs has proved difficult to attain and in others the safe 
delivery of constructs to cancer cells in vivo remains a challenge [87,88]. 
 
 
ABCs mainly involved in MDR: ABCB1, ABCC1 and ABCG2 
 
Fulfilling their role in detoxification, several ABC transporters have been found to be 
overexpressed in cancer cell lines. In humans, the three major types of MDR proteins include 
members of the ABCB (ABCB1/MDR1/P-glycoprotein), the ABCC (ABCC1/MRP1, 
ABCC2/MRP2, probably also ABCC3–6, and ABCC10–11), and the ABCG (ABCG2/MXR/ 
BCRP) subfamily [27].  
 
ABCB1, also known as MDR1 or P-gp (P-glycoprotein), was the first ABC transporter 
discovered, cloned and characterized through its ability to confer a multidrug resistance 
phenotype to cancer cells that had developed resistance to chemotherapy drugs [16,89-91].  
ABCB1 has a four-domain structure, as is typical of most eukaryotic ABC transporters, with 
two NBDs each preceded by a MSD composed of six transmembrane helices (MSD-NBD-
MSD- NBD) [65]. 
ABCB1 has been demonstrated to be a promiscuous transporter of hydrophobic substrates 
including drugs such vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes [92] as 
well as lipids, steroids, xenobiotics, and peptides [93]. ABCB1 is thought to play an important 
role in removing toxic metabolites from cells but is also expressed in cells at the blood–brain 
barrier, where presumably plays a role in transporting compounds into the brain that cannot be 
delivered by diffusion and in adrenal gland where it is involved in steroid hormones excretion 
[27].  
ABCB1 is expressed in many cell types such as brain, including choroid plexus, astrocytes, 
microglia, and capillary endothelium where the protein prevents the passage of drugs and 
toxins into the brain [94,95]. It is also expressed in apical surface of proximal tubule cells of 
the kidney, in luminal membranes of cells of the gastrointestinal tract, in the canalicular 
membranes of hepatocytes liver. Lower levels are expressed in the placenta, the adrenal 
cortex, and CD34+ hematopoetic stem cells [96,97]. 
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The expression in the apical membranes of the epithelial cells have an important role in 
regulating drug distribution since ABCB1 influences drug distribution in three ways: it limits 
drug absorption in the gastrointestinal tract; it promotes drug elimination in the liver, kidney, 
and intestine; and it regulates drug uptake. The orally administration of drugs in abcb1 
knockout mice lead to a 50-100 fold increase in drug accumulation in tissues especially in 
brain where ABCB1 plays a predominant role in toxins defence [98,99]. 
Since its role in detoxification, in tumours ABCB1 become overexpressed and there are 
evidences linking the protein expression with a poor clinical outcome with a reduction in 
response to chemotherapy in breast cancer, sarcoma and certain types of leukaemia [100,101]. 
In HCC ABCB1 overexpression has been reported to be associated with shorter overall 
survival [102,103], interestingly Ng and Coll. [104] found this association only in patients 
previously treated with chemotherapy. The high-level expression ABCB1 in tumours is either 
due to gene amplification or to elevated level of transcription [105]. 
Overexpression of this transporter raised the possibility that oncogenes or tumor suppressor 
genes may regulate constitutive ABCB1 expression. The proteins p63 and/or p73 in certain 
types of tumors play a complex role in the regulation of ABCB1, which may depend on the 
cellular environment, the cytotoxic drug used during selection or treatment, and mutations in 
p53 [106-109]. 
Many ABCB1 inhibitors were discovered (Verapamil, Tariquidar, Disulfiram and others) and 
despite promising in vitro results, using several resistance cell models [26,110], successful 
modulation of clinical MDR through the chemical blockage of drug efflux from cancer cells 
remains elusive [26,65]. 
 
ABCC1 was first member of ABCCs subfamily being cloned 1992 from drug-selected human 
lung cancer cell line H69AR [111,112]. Initially it was identified as multidrug resistance-
associated protein (MRP) and subsequently multidrug resistance protein 1 (MRP1). ABCC1 
do not respect the typical structure of an ABC (Fig. 4) since it is composed of five domains 
with an extra NH2-proximal MSD which has five TM segments and an extracytosolic NH2-
terminus (MSD–MSD–NBD–MSD–NBD) [111,113,114]. The ABCC1 protein is thought to 
play both a role in protecting cells from chemical toxicity and oxidative stress and to 
participate in inflammatory due its active role in the transport of leukotrienes such as 
leukotriene C4 (LTC4) [115]. Despite structural differences there is considerable overlap with 
others ABCs in the spectrum of drugs to which ABCC1 confer resistance. 
Introduction 
 
15 
 
The ABCC1 pump confers resistance to doxorubicin, daunorubicin, vincristine, colchicines, 
and several other compounds, very similar profile to that of ABCB1 [116]. However, unlike 
ABCB1, ABCC1 transports drugs that are conjugated to glutathione by the glutathione 
reductase pathway [57,115,117,118].  
Several ABCC1 inhibitors or reversing agents were developed such as Verapamil, PSC-833, 
Laniquidar, Disulfiram, all of this agents failed the clinical trial test since they do not 
ameliorate patients’ outcome or worse, they owed secondary toxicity [26]. 
ABCC1 is expressed in most tissues throughout the body with relatively high levels found in 
the lung, testis, kidneys, skeletal muscle and peripheral blood mononuclear cells, while less 
amount is found in liver [52,111,119]. In most tissues ABCC1 is localized to the basolateral 
cellular surface, which in certain tissues results in the efflux of its substrates into the blood. 
High levels of ABCC1 expression has been found in non-small cell lung cancer (NSCLC) and 
have been correlated with a higher grade of differentiation of NSCLC, particularly in 
adenocarcinoma [120-122]. Despite the higher grade of differentiation that might be expected 
to have a better prognosis, the higher expression of ABCC1 is a negative indicator of response 
to chemotherapy and overall survival for these kind of tumours [123-125]. 
Several independent studies indicate that ABCC1 expression is a negative prognostic marker 
for some types of breast cancers associated with shorter times to relapse and reduced overall 
survival [120,126,127]. In prostate cancer ABCC1 expression levels have been reported to 
increase with cancer stage and invasiveness [128] and to be positively associated with mutant 
p53 status of the tumor which is reported to be a suppressor of MRP1/Mrp1 transcription 
[128-130]. 
ABCC1 expression is reported to increase in severe human liver disease [131] and in 
hepatocellular carcinoma where it is associated with a more aggressive tumour phenotype 
[132,133]. Despite the increased ABCC1 expression in liver malignancies some studies 
reported no statistically significant difference in ABCC1 expression levels between the 
neoplastic and perineoplastic tissue [132]. Moreover Nies and Coll. evidenced no role for 
ABCC1 in MDR phenotype in HCC [134]. 
 
ABCG2 (MXR/BCRP/ABCP) is a so-called half-transporter consisting of a single 
hydrophobic MSD predicted to contain 6 TM helices preceded by a single NBD (NBD-MSD) 
[29], it is an atypical ABCG subgroup member since it has a large extracellular loop between 
TM5 and TM6. It was cloned independently from two drug selected cell lines and a human 
cDNA library and was given three different names. In the first study it was isolated from a 
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multidrug-resistant breast cancer cell line co-selected in doxorubicin and verapamil (a 
ABCB1 inhibitor) in an effort to elucidate non-ABCB1 mechanisms of drug resistance 
[29,135]. Although the first name suggested from this study was Brest Cancer Resistance 
Protein (BCRP), there is no evidence at present that this transporter is preferentially expressed 
in normal or malignant breast tissue and its clinical relevance is not yet well established.  
Subsequently it was isolated from a mitoxandrone resistant cell lines and named Mitoxantrone 
Resistance Protein (MXR) [136] and last from a human cDNA library from placenta (ABCP) 
[137]. 
As the others ABC transporters ABCG2 is widely expressed around the body. In lung it 
appears low but detectable, and is found in the epithelial layer and seromucinous glands 
[138]. It is expressed at the apical surface of the epithelial cells throughout the small intestine 
and colon preventing and/or modulating the passage of certain xenobiotics or their 
metabolites from the gut into the circulation [139-141]. It is highly expressed at the luminal 
surface of brain capillaries [142,143] where it as a relevant role in the transport since both its 
mRNA and protein expression increases in ABCB1 knockout mice versus wild-type mice 
suggesting a compensatory up-regulation the absence of ABCB1 [142]. ABCG2 is highly 
expressed in the trophoblast cells of the placenta [144]. This suggests that the pump is 
responsible either for transporting compounds into the foetal blood supply or removing toxic 
metabolites [145]. It is also highly expressed in liver, where it localizes to the apical regions 
of canalicular cells and various stem cells.  
The high ABCG2 expression levels in “barrier” tissues indicate a key role in the protection of 
the body from xenobiotics, especially in the gastrointestinal track. Indeed ABCG2 transports a 
wide variety of anticancer agents, their partially detoxified metabolites, toxins, and 
carcinogens found in food products, as well as endogenous compounds [27,146]. 
As for ABCB1 the importance in protecting tissues become evident from knockout 
experiments where abcg2 (-/-) mice have elevated plasma levels and decreased intestinal, 
fecal, and hepatobiliary excretion of the food carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) [147] and an increased intestinal absorption and 
decreased biliary secretion of pheophorbide, a toxic compound derived from ingested food, 
expecially plant-derived nutrients or food supplements [148]. 
Fulfilling its role in detoxification ABCG2 have been found overexpressed in many cancer 
cell lines and human tumours especially in adenocarcinomas of the digestive tract, lung, and 
endometrium [149]. In retrospective studies the chemotherapy response rate in patients was 
found to be correlated with ABCG2 expression [150,151]. Regarding HCC at present, no 
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clear results associate ABCG2 expression with clinical outcome although some studies 
evidenced the up-regulation of both ABCG2 mRNA and protein in HCC [152]. 
In tumours ABCG2 confers resistance to a narrower range of anticancer agents than ABCB1 
and ABCC1. Nevertheless, the spectrum includes anthracyclines, mitoxantrone, and 
topoisomerase I inhibitors such as camptothecin. On the other hand, ABCG2 does not confer 
resistance to the vinca alkaloids, epipodophyllotoxins, paclitaxel, or cisplatin [153]. 
Recently was evidenced that ABCG2 is also able to alter absorption, metabolism and toxicity 
of Tyrosine Kinase Inhibitors (TKIs) such as Imatinib (STI-571) and Iressa (ZD 1839) [154]. 
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The figure represents human telomeres t-loop organization (a) with the main protein complexes involved in 
stabilization (b). Taken from De Lange et al. (2004) [160]. 
 
TASK 2. TELOMERASE SILENCING EFFECTS IN HCC 
 
 
Telomeres and cellular senescence 
 
The ends of linear eukaryotic chromosomes contain specialized structures called telomeres 
[155]. The telomeres consist of DNA-protein complexes, termed helterin complexes [156], 
that protect chromosome ends from end-to-end fusion and degradation. Telomeric DNA 
typically ends in a 3’ single-strand G-rich overhang of 50-300 nucleotides, which has been 
proposed to fold back onto duplex telomeric DNA forming a “T-loop” structure [157,158] and 
avoiding the linear ends of chromosome from being recognised as single and/or double-strand 
DNA breaks (Fig. 6). 
Telomere length varies among chromosomes and among species [159,160]. In human 
generally telomeric DNA consists of about 15–20kbp tandemly repeated G-rich sequences 
(TTAGGG) that form a molecular scaffold containing many binding sites for telomeric 
proteins, including TTAGGG repeat binding factor 1 (TRF1) and 2 (TRF2) (Fig. 6) [161]. 
TRF1 seems to regulate telomere length by inhibiting telomere elongation once telomeres 
reach a critical size [162]. TRF2, in contrast, suppresses end-to-end fusions chromosomes and 
serves to stabilize chromosome ends [163].  
Figure 6. Telomeres and t-loop organization. 
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The DNA-protein complexes are extremely dynamic especially during interphase when the 
telomere-bound proteins are rapidly exchanged on and off [164].  
Telomeres are subjected to progressive ends shortening at every cell cycle due to the inability 
of DNA polymerase to replicate the chromosome ends during lagging strand synthesis (“end 
replication problem”), oxidative damage and other processing events [165-167]. Cells that 
lack a compensatory mechanism to counteract this gradual loss exhibit a growth arrest state, 
called replicative senescence [168], that is thought to occur when one or more critically short 
telomeres trigger a p53 (and perhaps RB) -regulated DNA damage response [169,170]. 
Human cells can temporarily bypass this growth arrest when RB and p53 are disabled 
[171,172], but ultimately so many telomeres become critically shortened that multiple 
chromosome end fusions occur, resulting in loss of cell viability in a process termed “crisis”. 
Cellular senescence was discovered in the early 1960s, Leonard Hayflick observed that 
human cells placed in tissue culture stop dividing after a limited number of cell divisions by a 
process now known as replicative senescence [173]. Actively growing cells, such as 
embryonic stem cells, stem cells, lymphocites, some epithelials, and cancer cells posses 
several mechanism counteracting progressive telomere shortening and senescence. 
By virtue of its ability to repair telomeric DNA, the telomerase, a reverse transcriptase, plays 
a key role in preserving chromosomal stability and genetic integrity in eukaryotes leading to 
an anti-aging effect [174-178]. However telomerase dependent telomeres maintenance is not 
the only anti-senescence mechanism known.  
Some eukaryotic species have apparently completely lost the telomerase-mediated mode of 
telomeric DNA maintenance during evolution. In these organisms, the telomeric DNA is 
composed of other types of sequences, which provide exceptions to the usual type of 
canonical telomeric repeats. For example in the fruit fly Drosophila melanogaster, telomeres 
are primarily composed of a complex mosaic of large, non-LTR-type retrotransposons called 
HeT-A and TART elements [179]. Sporadically, one of these retrotrasposons is added onto 
the termini of chromosomes by a variant retrotransposition mechanism, counteracting over 
time the gradual sequence loss from chromosome ends. 
Yeasts can use a telomerase-independent Rad52-mediated DNA recombination mechanism to 
maintain telomeres stability [180-183], and a small percentage of tumours and immortalized 
human cell lines can utilize an apparently similar mechanism known as “alternative 
lengthening of telomeres” ALT [184], however these cells are less tumorigenic in mouse 
xenografts and they have weak metastatic potential [185].  
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 Table 1. Protein interactors of the telomerase holoenzyme 
components. 
The telomerase reverse transcriptase 
 
 
Telomerase was discovered by Carol W. 
Greider and Elizabeth Blackburn in 1984 
as novel telomere terminal transferase 
involved in the addition of telomeric 
repeats necessary for the replication of 
chromosome ends in the ciliate 
Tetrahymena [210].  
Subsequently telomerase was identified 
as a 650 to 670 kDa ribonucleoprotein 
(RNP) complex composed of hTERT 
(127kD), a catalytic subunit, dyskerin 
(57kD), a putative pseudouridine 
synthase [211], and a 451 nucleotide 
RNA (hTR or hTERC) (153kD). The 
ribonucleoprotein dyskerin, also known 
as NOLA4 (nucleolar protein family A, 
member 4), encoded by the DKC1 gene 
on the X chromosome, is a putative 
pseudouridine synthase within the class 
of H/ACA (Hinge-hairpin-ACA) box ribonucleoproteins [212]. It is required for proper 
folding and stability of telomerase RNA [213]. 
The RNA molecule carries the template for the addition of 6 base repeats (TTAGGG)n to the 
3’end of telomeres that became shorter due to incomplete extremities replication at every cell 
cycle or due to oxidative damage [214-217]. Other proteins are also associated with the 
complex such as GAR1, NHP2, NOP10 (also known as NOLA1, NOLA2 and NOLA3, 
respectively) and TEP1 which are proposed to aid the function and the location of the 
resulting telomerase complex [218]. 
Although telomerase is active as a monomer [219], from in vitro experiments there is 
evidence that telomerase in many others organism such as yeasts and human exists as a dimer 
[220-223] to which at least 32 distinct proteins have been proposed to associate (Table 1) 
[211]. Some of these components are necessary for telomerase attachment to the telomere at a 
certain cell cycle phase [224], while others are required for regulation of telomerase activity 
hTR hTERT RNP 
hTEP [186]  
Dyskerin [187] 
hStau [188] 
L22 [188] 
hGar1 [189] 
hNHP2 [190] 
hNOP10 [190] 
hnRNP C1 [191] 
hnRNP C2 [191] 
La [192] 
Ku70/80 [193] 
SmB [194] 
SmD3 [194] 
hNaf1 [195] 
PKCα [196] 
p23 [197] 
Hsp90 [197] 
p53 [198] 
c-Abl [199] 
PinX1 [200] 
SMN [201] 
Ku70/80 
[193,202] 
CRM1 [203] 
Ran [203] 
KIP [204] 
Nucleolin [205] 
MKRN1 [206] 
hPif1 [207] 
hEst1A [208] 
hnRNP A1 [209] 
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[225]. Some proteins are necessary for maturation of the telomerase complex and degradation 
of its components [226] most of which dissociate during the activation process [226].  
Normal human cells have hTERT distributed in the nucleolus and nucleoplasm, but in human 
cancer cells hTERT primarily locates in the nucleoplasm, and it is generally not detected in 
the nucleolus [227]. 
The human telomerase RNA subunit is expressed in both telomerase positive and telomerase-
negative tissues [228] as a consequence the expression of the human catalytic subunit gene 
(hTERT) seems to be the rate-limiting process for telomerase activity. 
In yeast, telomerase is not active at each telomere in every cell cycle [229]. Instead, individual 
telomeres might experience several rounds of shortening in successive cell cycles before a 
certain length is reached that will make telomerase more likely to act on them. Indeed 
telomerase preferentially associate with short telomeres, compared to unshortened ones and 
this association markedly increased in S phase or G2/M, apparently being coupled with DNA 
replication [230-233]. 
Without telomerase, the cycle of alternating lengthening and shortening of telomeres in 
dividing cells is broken. As a result, telomeres progressively shorten, and as the cells divide, a 
gradually increasing fraction of the cells exit the cell cycle until the cell population senesces 
[234]. In some mammalian cells, apoptosis is also provoked. 
Human cells that overexpress both the RNA and protein components of telomerase experience 
continuous telomere elongation that is independent of telomere length [235]. This suggests 
that limiting amounts of telomerase might be an important factor in ensuring the preferential 
elongation of the shorter telomeres and might help to explain the role of negative regulators of 
overall telomerase activity such as PinX1 [236]. The protein PinX1 [200,237] is a negative 
regulator of telomerase that interacts with hTERT via the RNA-binding domain (TRBD). The 
role of the interaction of hTERT with PinX1 is still unknown. It is supposed that in this way 
hTERT not bound to hTR is “preserved” in an inactive state [236]. PinX1 it is often found to 
be diminished in amount in human cancers thus it could be considered as tumor suppressor 
[237]. 
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Telomerase expression profile 
 
During embryonic development, human telomerase activity is detectable at the blastocyst 
stage and in most embryonic tissues although before 20 weeks of gestation is subsequently 
lost [238]. Fetal tissues show temporally distinct patterns of regulation, with activity 
remaining longer in liver, lung, spleen and testes than in heart, brain and kidney [239]. In 
heart tissue, loss of activity occurs concomitant with loss of hTERT mRNA expression; loss 
of activity in kidney instead occurs concomitant with a change in the pattern of hTERT 
expression [240]. Although telomerase expression is restricted to embryonic stem cells, in 
adulthood a weak expression is detectable in activated stem cells [238,241,242], grow-
stimulated lymphocytes, uroepithelial cells [243], intestinal epithelium [244], esophageal 
epithelium [245], cycling endometrium [246], basal keratinocytes [247], cervical epithelium 
[248], and hematopoietic stem cells [249]. All the other somatic cell types do not express 
telomerase. 
These various telomerase-positive human somatic cell types produce different relative 
amounts of catalytic activity, this is because of cellular telomerase activation does not 
necessarily act to maintain a constant telomere length. In some cases, telomeres erode with 
cell proliferation despite telomerase activation [250,251], in other cases, telomeres make 
dramatic gains in net length despite cell proliferation [252]. Moreover the telomerase 
activation in human somatic cells is transient, not within a given cell cycle out over the course 
of multiple cell divisions. A stem or progenitor cell with weak telomerase activity can 
generate strongly telomerase-positive lineage-committed descendants, which will 
subsequently lose telomerase activity with additional differentiation [252-254]. This transient 
telomerase activation in normal human somatic cells contrasts sharply with the constitutive 
activation of telomerase in most cancers. 
In contrast to its physiological expression pattern, telomerase become up-regulated in many 
cancers since the maintenance of a correct replicative status is an essential step in 
tumorigenesis. Telomerase is overexpressed in 85–90% of human cancers and over 70% of 
immortalized human cell lines [241,255], particularly in cancers telomerase activity is highly 
increased by up to 100-fold of expression in tumoral portions in respect of the adjacent 
normal cells [253]. Telomerase expression in cancers and immortalized cells is usually 
associated with a short and stable telomere length [184,256-258]. 
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Telomerase expression in HCC 
 
Telomerase is overexpressed in 80-100% of human HCCs and its expression is positively 
correlated with its activity [259-261]. The tumor-surrounding affected tissue presents a 
weaker telomerase activity, generally this observation is more frequent in cirrhosis than in 
hepatitis [260], however there is not a general agreement with this statement among the 
several studies in this field [262,263]. 
Some reports did not observe any correlation between telomerase expression with tumoral 
progression [262-264] whereas other studies reported that the telomerase activity 
progressively increases during the dedifferentiation process of HCC from well-differentiated 
to poorly differentiated HCC [265-267]. These observations support strongly that the high 
enhancement of telomerase expression is an essential event for malignant transformation 
during hepatocarcinogenesis like other malignant cancers and for the immortality of the 
transformed cells.  
It worth to be noticed is that in all studies no telomerase expression was detected in non 
diseased liver [259,260] reinforcing the relationship between cancer and telomerase 
expression. 
 
 
Telomerase and cellular immortalization  
 
Due to its pivotal role in stabilizing telomeric DNA and in preventing telomere shortening-
induced cell proliferative senescence [268-271], telomerase is required for immortalization of 
primary cells. 
When placed into culture, most normal human somatic cells have a limited lifespan. Human 
fibroblasts, for example, can divide an average of 40 to 50 generations before they stop 
dividing [272]. Transformation with viral and/or cellular oncogenes extends the lifespan of 
human cells beyond the first growth arrest point, known as senescence, but these transformed 
cells eventually enter a phase known as crisis, where cells suffer chromosome aberrations and 
massive cell death [273,274]. Rare immortal cell clones escape from crisis and survive by 
telomerase activation. From this observation became evident the role of telomerase for cell 
immortalization. In some reports the ectopically induced overexpression of the reverse 
transcriptase subunit of telomerase (hTERT) activates the telomerase activity and indefinitely 
extended the proliferative lifespan of fibroblasts [268]. Although telomerase expression is 
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sufficient to immortalize some cell types, such as fibroblasts, other cell types require the 
cotransfection of an oncogene for the inactivation of other growth suppressing pathways and 
thereby for direct immortalization [275]. For example the cotransfection of SV40 large 
antigen, mutant H-ras, and the hTERT gene has been shown to be capable of transforming 
both human fibroblasts and human epithelial cells into tumor cells [276]. In these cells 
telomerase is not only necessary for maintaining the immortality of the cells [277] but, in 
certain cases it also increases cell proliferation and invasion ability [278]. This definitively 
shows that hTERT expression, and presumably the resultant telomerase activation represents 
an important step in tumor development. 
 
 
Genetic modulation of telomerase activity  
 
Telomerase levels are 
regulated at multiple levels 
including transcription, 
alternative splicing, assembly, 
subcellular localization, and 
post-translational modifica-
tions of various components and of the enzyme complex itself.  
Telomerase activity mainly depends on hTERT availability since the RNA component is 
ubiquitously expressed in somatic cells. The transcriptional regulation of hTERT is 
determined by the binding of either repressors or activators to the core promoter which is 
essential for transcriptional activation in cancer cells and immortalized cells. However, the 
exact molecular mechanism underlying the tumor-specific expression of telomerase remains 
unclear.  
Transcriptional activators include c-Myc [279], Sp1 [280,281], estrogen [282] and USF1 and 
2 (upstream stimulatory factor) [283]. Transcriptional repressors include the tumor suppressor 
protein p53 [284,285], Mad1, myeloid-specific zinc finger protein 2 (MZF-2) [286], Wilms’ 
Tumor 1 (WT1) [287], TGF-h and Menin [288] (Fig. 7). Overexpression of p53 can trigger a 
rapid downregulation of hTERT mRNA expression [284,285]. However, the inhibition of p53 
activity failed to reactivate hTERT expression [289] suggesting the involvement of others 
regulators in hTERT expression. 
 
Figure 7. Core promoter region of hTERT. 
Taken from Liu et al. (2004) [288] 
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p53 inhibits Sp1 binding to the hTERT promoter by forming a p53-Sp1 complex [285]. 
Indeed the mutations in all five Sp1 binding sites abolished the p53-mediated hTERT 
promoter repression. Menin can bind directly to the hTERT promoter, whereas TGF-h acts 
through Smad-interacting protein-1 (SIP1) [289]. The presence of MZF-2 significantly 
represses hTERT transcription [286], but it is assumed to play a minor role in the regulation 
of hTERT.  
Mad1 and c-Myc play antagonistic roles in the regulation of hTERT, they both bind to the 
consensus sequence 5V-CACGTG-3V, called an ‘‘E-box’’ [280,290]. High levels of c-Myc 
often correlate with high levels of hTERT, and high levels of Mad1 are observed in cells with 
repressed hTERT [291]. c-Myc is an oncogene and its product complexes with Max protein as 
a heterodimer to activate gene transcription [292]. c-Myc/Max heterodimer binds at the E-
boxes after induction of cellular transformation [293] whereas there is a preferential binding 
of the Mad1/Max heterodimer at the E-boxes of the hTERT promoter in untransformed cells 
[293]. The hTERT regulatory region contains two estrogen response element (ERE) and an 
increased transcription of hTERT follows the binding of the hormone estrogen and its 
receptor to ERE [282]. 
Located within the hTERT promoter there are clusters of CpG dinucleotides [294] that are 
targets for DNA methylation generally leading to gene silencing. The methylation state seems 
not to clearly correlate with hTERT expression since contrasting data are available in 
literature [295-297]. This could be due to the involvement of a large variety of transcription 
factors interacting with the hTERT promoter.  
 
 
Telomerase post-transcriptional regulation 
 
To date, seven alternatively spliced sites (ASPSs) in the hTERT mRNA have been described 
[298-300]. Two ASPSs, α-deletion and γ-deletion, result from in-frame deletions of exonic 
sequences in exon 6 and 11, respectively, and the β-deletion variant derives from an exon 7 
and 8 deletion.  
Some of these hTERT inactive mutants can negatively influence telomerase activity such as 
the α-and β- deletion variants [301,302]. It was postulated a role of this mutants in binding 
most of the components needed to form the ribonucleoproteins such as hTR, resulting in a sort 
of competition with the wild-type forms for binding to the telomeres. Moreover the 
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Figure 8. Telomerase domain structure 
dimerization of the wild-type and mutant telomerase may create a non-functional heterodimer 
more susceptible to degradation [303]. 
Mitomo and coll. [304] demonstrated that also miRNAs can play a critical role in telomerase 
regulation. In particular miR-138 targets specificity the hTERT 3’-untranslated region 
consequently inducing a reduction in hTERT protein expression [304]. On the contrary the 
loss of miR-138 expression may partially contribute to the gain of hTERT protein expression.  
 
 
Telomerase structure and domain organization 
 
The telomerase RNA and protein subunit 
form the enzyme catalytic core, being 
sufficient to reconstitute catalytically-
active telomerase in vitro. The telomerase 
RNA has diverged considerably in size 
and sequence during evolution, 
nonetheless conserving some structural elements. The amino acid sequence of telomerase 
catalytic subunits is more conserved among species, especially in residues involved in 
important functions such as catalysis, nucleotide binding, and ribo- and deoxynucleotide 
recognition [229]. 
hTERT contains four major functional domains (Fig. 8):  
- N-terminal TEN domain containing moderately conservative GQ motif (hypomutable 
domain I) [305], the TEN domain participates in the interaction with DNA primer and 
influences the enzyme activity [306]. 
- RNA-binding domain (TRBD domain) contains the conservative motives CP, QFP, and T 
(hypomutable domains II, III, and IV). Motifs CP and T directly participate in RNA 
binding while motif QFP has a structural function. 
- Reverse transcriptase domain (RT domain) containing seven conservative domains and an 
IFD site (Insertion in Fingers Domain) which is located between motifs A and B and it is a 
distinctive feature of telomerases [307]. 
- Lowly conserved C-terminal domain (CTE domain) that binds the RNA/DNA hybrid and 
catalyze the addition of DNA repeats onto the 3’ end [308]. 
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Such organization of hTERT domains results in formation 
of a central “hole” of sufficient width for the 
accommodation of a 7-8 bp long nucleic acids double-
strand. In yeast telomerase was also detected an 
endonuclease activity however, the telomerase domain 
responsible for nuclease activity has not been identified.  
hTR contains secondary structure elements necessary for 
catalytic functions, type I and II processivity, as well as 
elements necessary for maturation, telomerase stability, 
and hTR localization. 
hTR contains four conserved structural domains:  
- The pseudoknot, the core domain, which includes the 
template. 
- The conserved regions 4 and 5 (CR4/CR5), which 
together comprise the catalytic core of the TR. 
- The box H/ACA that binds the H/ACA RNP proteins 
(dyskerin, Gar1, Nop10, Nhp2) the CR7 [309] (Fig. 9). 
In mammals hTR is synthesized by RNA polymerase II, 
then it is capped at the 5’ end, modified, and processed at 
the 3’ end [194,216].  hTR processing and stability depends 
on H/ACA that associates dyskerin, hGAR1 hNHP2 and 
hNOP10 [187,189,190]. Although the H/ACA motif is necessary to hTR accumulation it is 
not sufficient, there is another motif at the distal end of the 3' H/ACA motif hairpin that is 
also required for RNA stability in vivo [310,311]. The complexes protein/hTR are generally 
referred as “telomerase RNA” and they accumulate ubiquitously in cells regardless of the 
presence of telomerase activity in cell extracts [216]. Once hTR is preassembled into stable 
telomerase RNP, hTERT associates by interactions with two independent regions of 
telomerase RNA: The template region (including nucleotides 44 ± 186) and a putative double 
hairpin element in the 5' stem of the H/ACA domain (a region within nucleotides 243 ± 326). 
The functional telomerase enzyme assembly in humans is dependent from chaperones such as, 
heat-shock protein-90 (HSP90) and p23 chaperones that seem to participate in the assembly, 
disassembly and degradation of telomerase complexes [197,312]. 
 
 
Secondary structure and known 
protein components of the human 
telomerase RNA (hTR). The hTR core 
and CR4/CR5 domains independently 
bind the hTERT (blue ellipse). The 
hTR scaRNA domain binds two sets of 
the four H/ACA RNP proteins: 
dyskerin (green), Gar1 (cyan), Nop10 
(magenta), and Nhp2 (orange). The 
protein TCAB1/WDR79 (purple) 
binds both the dyskerin and the CAB 
box located at the CR7 region within 
the H/ACA scaRNA domain. Taken 
from Zhang et al., (2011) [309]. 
Figure 9. Architecture of human 
  telomerase RNA. 
Introduction 
 
28 
 
The figure represents the telomerase reaction cycle. In orange the reverse transcriptase domain (RT), in 
green the TEN domain and in blue the TRBD domain. The telomerase RNA (hTR) with the template site 
(orange rectangle) is maintained in the correct position through interaction between the telomerase domains 
in the anchor sites. 1) Enzyme is not bound to primer. 2) Primer annealing in PAS1, the primer 3’ end is 
positioned in correspondence of residue 49 of hTR (catalytic site). 3) Elongation stage. 4) Completion of a 
single telomeric repeat synthesis and enzyme translocation along the primer. In red the newly synthesized 
DNA portions. Grey arrows point to possible processes of primer dissociation during enzyme functioning. 
The catalytic cycle of telomerase 
 
The cycle of in vitro telomerase reactions (Fig. 10) includes the following stages: primer 
binding, elongation, translocation, and dissociation. The first step of the telomerase cycle is 
the recognition of the template from the enzyme. However the mechanisms that underlie the 
recognition of a single-stranded-DNA substrate seem surprisingly variable between 
holoenzymes and have not yet been well characterized [313,314]. Interaction assays and high-
resolution structure have evidenced the presence of a binding surface for single-stranded 
DNA, termed PAS1 (primer/product alignment/anchor site-1), that is partially located in the 
TEN domain and adjacent to the template hybrid (Fig. 10).  
 
 
 
From ciliate and vertebrate models was discovered another DNA-interaction specificity 
domain termed PAS2. PAS2 sites could be contiguous with or separated from PAS1 and are 
proposed to account for the enhanced binding affinity of longer primers with the telomerase 
holoenzyme [313,314]. Single-stranded DNA binds to PAS1 with the 3’ end near the hTR’s 
Figure 10. Telomerase reaction cycle. 
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template region. The hRT is maintained in the correct position by interactions with the TEN 
and the TRBD domains of the hTERT subunit. In particular the 3’ and the 5’ anchor sites of 
hTR are located in the TEN and TRBD domains respectively (Fig. 10). These interactions 
allow the positioning of the residue 49 of the hTR in the active site. The 3’ end the DNA 
primer locates in correspondence of residue 49, once the first 6 bases are added the enzyme 
translocates along the template to add the others 6 base repetitions without separation from 
the primer. 
The ability for translocation is connected with enzyme processivity. Two types of telomerase 
processivity are distinguished [314]. Processivity I is the telomerase capability for RNA-DNA 
duplex translocation in the active center after each nucleotide addition at the stage of 
elongation. Processivity II is telomerase capability for translocation relative to the bound 
DNA primer after addition of one telomeric repeat, after which the primer again becomes 
capable of elongation. Human and protozoan telomerases in vitro exhibit type II processivity. 
They are able to add hundreds of nucleotides to telomeric substrate via multiple completions 
of telomeric repeats along their RNA template [315].  
 
 
Telomerase recruitment to telomeres and telomerase regulation 
 
Telomerase is regulated in cis at individual chromosome ends by the telomeric protein/DNA 
complex in a manner dependent on telomere repeat-array length. A dynamic interplay 
between telomerase-inhibiting factors bound at duplex DNA repeats and telomerase 
promoting ones bound at single-stranded terminal DNA overhangs appears to modulate 
telomerase activity. 
Telomeres structure by itself act as an inhibitor of telomerase activity since the terminal t-loop 
structures sequester the 3’ telomeres end avoiding the interaction with telomerase. The t-loop 
is formed when the G-reach 3’-single-stranded telomeric end penetrates the double stranded 
region where the displaced second strand forms an internal D-loop [157,316]. Nevertheless 
there may be an interval within S phase when t-loops are disassembled by the DNA 
replication machinery which provides the best opportunity for telomerase access to a 
chromosome 3' end. 
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In budding yeast telomerase activation is telomere length dependent. The protein Rap1 is the 
main responsible of telomerase inhibitors recruitment due to its ability to bind double-
stranded telomeric repeats via Taz1 (Fig. 11B). The Rap1 C-terminal domain (RCT) interacts 
with Rif1 and Rif2 that independently relay the inhibitory signal to telomerase [317,318]. 
Longer telomeres, by carrying a larger number of Rap1 binding sites, allow increased 
association of telomerase repressors that inhibit the MRX (Mre1/Rad50/ Xrs2) complex 
binding to telomeres and as a consequence telomerase is largely inhibited at these ends. 
The telomere shortening reduce the binding sites for telomerase inhibitory complexes (Fig. 
12) allowing, during S phase, the association of the MRX (Mre1/Rad50/ Xrs2) to telomeres 
leading to Tel1 kinase recruitment through an interaction with the C-terminus of Xrs2 and 
subsequent phosphorylation of Cdc13 on serine residues. The protein Cdc13, a single-
stranded DNA-binding protein associates with TG-rich telomeric repeats, and its expression 
peaks in late S phase concomitant with the appearance of long overhangs [319] (Fig. 12). 
Recently, Cdc13 has indeed been shown to be phosphorylated in vitro by the Tel1 and Mec1 
checkpoint kinases (orthologs of mammalian ATM and ATR, respectively) on several serine 
residues, two of which are required for telomere maintenance [320]. Indeed cells lacking both 
Figure 11. Telomeres and telomerase recruitment 
Schematic representation of the telomeric complexes responsible for telomerase regulation in mammals (A) and yeasts 
(B). (A) In mammalian cells, t-loops are proposed to be non-permissive for telomerase activity due to sequestration of the 
telomere terminus. Opening of the t-loop could be in itself sufficient to allow telomerase to act (middle). Alternatively, 
even in this unfolded state, the 3’ end might conceivably be made unavailable as a substrate for telomerase by (for 
example) interaction with shelterin-bound TPP1-POT1. If so, possibly a structural transition might have to take place that 
would unlock the telomerase-stimulatory activity of POT1-TPP1.  
(B) Similarly, in fission yeast, the Pot1/Tpz1/Ccq1 complex might be conductive to telomerase recruitment/stimulation 
only when in a proper configuration (i.e., when bound directly to the overhang) and/or postranslationally modified state. 
Poz1-mediated binding of the complex to Taz1-Rap1 is proposed not to be conductive of telomerase-promoting action. 
Modified from Bianchi et al. (2008) [317]. 
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                  Taken from Bianchi et al. (2008) [317]. 
kinases undergo telomere shortening and 
senescence [321]. Phosphorylated Cdc13 interacts 
with Est1 [322] which itself associates with the 
telomerase RNA (Tlc1) and then Est2 (the 
catalytic subunit of yeast telomerase) (Fig. 12). 
In mammals the DNA binding function is 
supplied by two orthologs of Taz1, TRF1 and 
TRF2, that bind as homodimers to double-
stranded telomeric repeats (Fig. 11A). TRF1 and 
TRF2 interact with each other via TIN2 protein 
that recruits TPP1 and its partner POT1; TRF2 
also binds RAP1. This overall structure on 
mammalian telomeres forms a six-protein-
complex TRF1/TRF2/RAP1/TIN2/TPP1/POT1) 
named shelterin complex [156] (Fig. 11A). 
Shelterin has an inhibitory effect on telomere 
lengthening, which appears to be exerted largely 
by structural changes at telomeres that may alter 
telomerase accessibility. Indeed TRF2 promotes a 
t-loop formation in vitro [323]. Moreover the 
POT1-TPP1 complex binds telomeres terminal 
overhangs with higher affinity and can also bind 
the shelterin complex via TIN2 interaction. The 
simultaneous interaction with overhangs and TIN2 could sequester the telomere terminus in a 
conformation non-accessible for telomerase and this interaction could be removed following 
secondary modification (for example, phosphorylation) [324-326] (Fig. 11A). The inhibitory 
effect of the shelterin complex increases with the number of complexes bound to the telomere 
arrays which clearly depends on telomere length [325,327]. Several studies, primarily using 
RNA-interference and dominant-negative alleles, have revealed the importance of every 
single component of the shelterin as negative regulator of telomerase including TRF1 and 
TRF2 [327], RAP1 [328-330], TIN2 [331,332], and POT1/TPP1 [325,332-335]. The switch 
from an inhibitory state to a telomere elongation promoting one depends on the balance 
between repressing and promoting factors. When telomeres reach the critical length some not 
well defined signaling pathways leads to telomerase activation. By analogy with the yeast 
Figure 12. Telomeres shortening and telomerase 
activation in yeasts. 
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systems, human RAP1 interacts, probably directly, with the MRN complex 
(MRE11/RAD50/NBS1) and Ku86 [330] which recruitment to telomeres leads to ATM-
dependent phosphorylation of TRF1 and to its dissociation from telomeres [336]. In an in vivo 
repressing state TRF2 binds to and inhibits ATM (ataxia telangiectasia mutated), Tel1 
homologue [337], the effect of TRF2 on ATM depends on the number of TRF2 bound at the 
telomeres. Telomeres shortening and TRF2 removal might activate [337] the ATM-dependent 
phosphorylation of TRF1 that dissociate from telomeres and further exacerbate the loss of 
TRF molecules from telomeres, with consequent amplification of the signal for the activation 
of telomerase.  
In human breast cancer telomerase was shown to be regulated by phosphorylation in both 
TERT and TEP1 subunits by Protein phosphatase 2A and protein kinase Ca [196,338]. 
Phosphorylation is associated with high telomerase activity, and dephosphorylation with low. 
 
 
Telomerase: the extratelomeric effects 
 
One of the most interesting findings in recent years is the discovery that telomerase functions 
are not limited to telomeres maintenance in cancer cells. A wide variety of non-canonical 
effects of telomerase that are independent of telomere lengthening have been discovered. In 
particular, inhibition of apoptosis seems to be a general function of this enzyme [339], 
telomerase expression directly inhibits apoptosis by blocking both the mitochondrial [340] 
and the death receptor pathway [341] through unknown mechanisms. The anti-apoptotic 
effect can also be conferred by catalytically inactive forms of hTERT and is therefore 
activity-independent [342-344]. Telomerase seems to actively promote cell growth; indeed it 
induces growth-related proteins such as epidermal growth factor receptor (EGFR) in 
mammary epithelial cells [345] and interferes with the TGF-beta network of growth factors in 
primary murine cell lines [346].  
Telomerase has a clear effect on the DNA repair machinery; cells in which telomerase activity 
was suppressed had a significantly impaired DNA damage repair [347]. The effect on DNA 
repair is dependent on catalytic activity, although the precise mechanism is not known [347].  
Telomerase has also a mitochondrial targeting sequence [348] but its role in the mitochondria 
is unclear at present. Notably, Ahmed and coll. [349] found that oxidative stress induces 80-
90% of all telomerase molecules to enter the mitochondria where it has been suggested to 
directly bind the mtDNA [349].  
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The telomerase that remains in the nucleus is insufficient to maintain telomere length and 
only a re-introduction of this enzyme into the nucleus can rescue telomeres lengthening [349]. 
Also single telomerase components have been proven to exert some specific functions; hTR, 
for example, was shown to modulate the DNA damage responses and increases cell viability 
after UV irradiation by impairing damage checkpoint activation [350]. This may explain why 
hTR is widely expressed in somatic cells and why it is upregulated in cancers and promotes 
growth even before hTERT is activated [351]. 
 
 
Dyskeratosis congenita 
 
Telomerase deficiency in humans was first described in the disease dyskeratosis congenita 
(DC). Patients with DC share signs of insufficient cellular renewal in the skin with an excess 
in skin pigmentation due to a decrease in keratinocyte turnover, an increase in melanin 
synthesis associated with melanocyte senescence [352] or aberrant melanin uptake, an 
exhaustion of epithelial stem cells that cause nail dystrophy. Moreover DC is characterized by 
bone-marrow failure with an insufficient renewal in blood cell counts that cause the premature 
dead of affected patients [353,354]. Interestingly long surviving DC patients show an 
increased risk of cancer [355], indeed prematurely short epithelial cell telomeres would 
enhance genomic instability [356]. 
The predominant X-linked inheritance of DC arises from substitutions in the RNA-binding 
protein dyskerin. The inability of mutated DKC1 to bind hTR determines the accumulation of 
the telomerase RNA subunit which is not assembled with hTERT to form active enzyme. 
Telomerase deficiency leads to premature telomere shortening, which in turn limits the 
renewal capacity of highly proliferative cell types in skin and blood. The less common, and 
generally less severe, autosomal dominant (AD) inheritance of DC depends on mutations in 
the H/ACA region of human telomerase RNA [357]. Other autosomal diseases, detected in 
patients with blood diseases, are associated with mutations in hTERT [358].  
The phenotypic and molecular differences between X-linked and AD disease suggest that the 
greater the telomerase deficiency, the greater the disease severity, indeed the twofold 
reduction in hTR predicted in AD DKC would limit maximal catalytic activation to 50% of 
actively growing cells that usually employ more than 50% of the holoenzyme maximum in 
the effort of telomere maintenance.  
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AIMS OF THE STUDY 
 
HCC is currently one of the most common worldwide causes of cancer death counting 
560,000 new cases per year. OLT or liver resection represent the best treatments for HCC. 
However, most patients cannot be subjected OLT or resection, and a good alternative is 
represented by chemotherapy or chemoembolization. Unfortunately the development of the 
MDR phenotype could lead to unsuccessful drug therapy. 
To understand and define ways to overcame this problem we developed a multitasking study 
in which the main objectives are: 
•  Analyse the drug-influenced expression profile of the main ABCs involved in MDR 
in HCC derived cell lines, in order to clarify the role of these transporters in liver 
malignancies.  
• Develop a new therapeutic approach that clear the hurdle of MDR. In particular 
targeting an essential and specific cancer related gene, such as telomerase could 
represent the new challenge in anticancer molecular techniques flanking conventional 
treatments. 
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MATERIALS & METHODS 
 
Chemicals and Reagents 
2X iQ
 TM
 SYBR Green Supermix - 170-8885 - Bio-Rad Laboratories - Hercules, CA, USA 
Anti-ABCB1 antibody - C219- Abcam plc, Cmmbridge, UK 
Anti-ABCC1 antibody - A23 -  Alexis Biochemicals, San Diego, CA  
Anti-ABCG2 antibody – BXP-53 - Abcam plc, Cmmbridge, UK 
Anti-Actin antibody - A2066 - Sigma-Aldrich, St.Louis, MO 
Anti-mouse secondary antibody - P0260 - Dako, Glostrup, Denmark 
Anti-rabbit secondary antibody - P0448- Dako, Glostrup, Denmark 
Anti-rat secondary antibody – P0450 - Dako, Glostrup, Denmark 
Bicinchoninic Acid Solution-KIT - B-9643 and 209198 - Sigma-Aldrich, St.Louis, MO 
Bovine pancreas insulin - I1882 - Sigma-Aldrich, St.Louis, MO 
bovine serum albumin - A7906 - Sigma-Aldrich, St.Louis, MO 
Cell Lysis Buffer (10X) – 9803 - Cell Signaling technology, Boston, MA 
Dexamethasone - D4902 - Sigma-Aldrich, St.Louis, MO 
DMEM high glucose - EC B7501L - EuroClone Milano Italy 
DMEM/F-12 (1:1)(Ham) 1X - 11039-021 – Invitrogen, Life Technologies Corporation, Grand Island, NY 
DMSO (dimethyl sulfoxide) - D5879-L - Sigma-Aldrich, St.Louis, MO 
Doxorubicin - D9891 - Sigma-Aldrich, St.Louis, MO 
EDTA (Ethylenediaminetetraacetic Acid) - 405497 - Carlo Erba Reagents, Milan, Italy 
Ethanol - 34852 - Sigma-Aldrich, St.Louis, MO 
FBS (Foetal bovine serum) - F7524 - Sigma-Aldrich, St.Louis, MO 
FITC (Fluorescein 5(6)-isothiocyanate ) - F3651 - Sigma-Aldrich, St.Louis, MO 
FITC conj. anti-rabbit secondary antibody (Alexa Fluor®) - A11008 -  Invitrogen, Life Technologies 
Corporation, Grand Island, NY  
Glycine - G4392 - Sigma-Aldrich, St.Louis, MO 
Hepes - H3375 -  Sigma-Aldrich, St.Louis, MO 
Hoechst H33258 - H6024 - Sigma-Aldrich, St.Louis, MO 
Laemmli Buffer 5X - 161-0737 - Bio-Rad Laboratories - Hercules, CA, USA 
L-glutamine 100X - EC B3000D - EuroClone, Milano Italy 
Luminata
TM
 Western HRP substrate - WBLUC 05500 – Millipore,  Billerica, MA 
methanol - 34860 -  Sigma-Aldrich, St.Louis, MO 
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide) - M2128 - Sigma-Aldrich, St.Louis, MO 
Nitrocellulose membranes - 162-0177 - Bio-Rad Laboratories - Hercules, CA, USA 
Normal Goat Serum - G9023 - Sigma-Aldrich, St.Louis, MO 
Paraformaldehyde - P6148 - Sigma-Aldrich, St.Louis, MO 
PBS (Dulbecco’s Phosphate Buffered Saline) - D5652-50L - Sigma-Aldrich, St.Louis, MO 
Penicillin/streptomycin 100X - EC B3001D - EuroClone Milano Italy 
Phenylmethylsulfonyl Fluoride - P-7626 - Sigma-Aldrich, St.Louis, MO 
PI (Propidium Iodide) - P4170 - Sigma-Aldrich, St.Louis, MO 
RNAse A – R6513 -  Sigma-Aldrich, St.Louis, MO 
RPMI 1680 - EC B9006L - EuroClone, Milano Italy 
Silencer®  siRNA Construction Kit AM1620 - Ambion, Invitrogen, Life Technologies Corporation, Grand 
Island, NY 
siLentFect Lipid Reagent for RNAi - 170-3360 - Bio-Rad Laboratories - Hercules, CA, USA 
Sodium acetate - S2889 - Sigma-Aldrich, St.Louis, MO 
Sodium bicarbonate - S5761 - Sigma-Aldrich, St.Louis, MO 
Sodium bicarbonate - S5761 - Sigma-Aldrich, St.Louis, MO 
Sucrose - S1888 - Sigma-Aldrich, St.Louis, MO 
the iScript
 TM
 cDNA Synthesis Kit - 170-8891- Bio-Rad Laboratories - Hercules, CA, USA 
TRAPeze® Telomerase Detection Kit – S7700 - Millipore Corporation, Billerica, MA 
Tri-Reagent Kit - T9424 - Sigma-Aldrich, St.Louis, MO 
Tris Base - T6066 - Sigma-Aldrich, St.Louis, MO 
TritonX100 – T8787 - Sigma-Aldrich, St.Louis, MO 
TWEEN 20 -  P7949 - Sigma-Aldrich, St.Louis, MO 
Williams E medium - W4128 - Sigma-Aldrich, St.Louis, MO 
β-mercaptoethanol – M3148 - Sigma-Aldrich, St.Louis, MO 
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Table 2. Real Time PCR amplification protocol. 
 
Gene Accession number Forward Primer Reverse Primer 
    
18S NR_003286.2 5’-TAACCCGTTGAACCCCATT-3’ 5’-CCATCCAATCGGTAGTAGCG-3’ 
β-actin NM_001101.3 5’-CGCCGCCAGCTCACCATG-3’ 5’-CACGATGGAGGGGAAGACGG-3’ 
ABCB1 NM_000927 5’-TGCTCAGACAGGATGTGAGTTG-3’ 5’-AATTACAGCAAGCCTGGAACC-3’ 
ABCC1 NM_004996 5’-GCCAAGAAGGAGGAGACC-3’ 5’-AGGAAGATGCTGAGGAAGG-3’ 
ABCG2 NM_004827 5’-TATAGCTCAGATCATTGTCACAGTC-3’ 5’-GTTGGTCGTCAGGAAGAAGAG-3’ 
Albumin NM_000477  5’-GTGGAAGAGCCTCAGAAT-3’ 5’-TTGGTGTAACGAACTAATAGC-3’ 
Aurora Kinase A NM_198433 5’-GAGAATTGTGCTACTTATACTG-3’ 5’-GGTACTAGGAAGGTTATTGC-3’ 
IL-6  NM_000600 5’-ACAGATTTGAGAGTAGTGAGGAAC-3’ 5’-GGCTGGCATTTGTGGTTGG-3’ 
IL-8  NM_000584 5’-GACATACTCCAAACCTTTCCAC-3’ 5’-CTTCTCCACAACCCTCTGC-3’ 
Midkine NM_001012334 5’-AAAGCCAAGAAAGGGAAG-3’ 5’-CTAACGAGCAGACAGAAG-3’ 
Survivin NM_001168 5’-CTAAGTTGGAGTGGAGTCTG-3’ 5’-GCTTGCTGGTCTCTTCTG-3’ 
Telomerase 
 hTERT subunit NM_198253 5’-CGTCTGCGTGAGGAGATC-3’ 5’-AAGTGCTGTCTGATTCCAATG-3’ 
TNF-α NM_000594 5’-GTGAGGAGGACGAACATC-3’ 5’-GAGCCAGAAGAGGTTGAG-3’ 
 
 
 
Step Cycle repeats Temperature Time 
    
PCR Reaction Cycle 1: (1X)  95°C 03:00 
 Cycle 2: (40X) 95°C 00:20 
  60 °C 00:30 
 Cycle 3: (1X) 95 °C 01:00 
Melting Curve Cycle 4: (1X) 55 °C 01:00 
 Cycle 5: (80X)  55 °C-94.5 °C 00:10 
 Cycle 6: (1X)                 4°C for Hold 
 
 
 
 
 
Table 1. List of the oligonucleotides used for Real Time PCR. 
Meterials & Methods 
 
37 
 
General procedures 
 
Cell lines and culture conditions 
 
SV-40 Immortalized Human Hepathocytes (IHH) were kindly provided by Dr. T.H. Nguyen 
[359] and were cultured in DMEM/F-12 (1:1) DMEM/F-12/(Ham) 1X with 10% (v/v)  FBS, 
1% L-glutamine 100X, 1% penicillin/streptomycin 100X, 5µg/mL bovine pancreas insulin, 
1µM dexamethasone. 
HuH-7  cells (differentiated human hepatoma)  were obtained from Japan Health Science 
Research Resources Bank (HSRRB, JCRB0403) and were cultured in DMEM high glucose 
with 10% (v/v) FBS, 1% L-glutamine 100X, 1% penicillin/streptomycin 100X. 
JHH6 (undifferentiated human hepatocellular carcinoma) were obtained from Japan Health 
Science Research Resources Bank (HSRRB, JCRB1030) and were cultured in Williams E 
medium with 10% (v/v) FBS, 1% L-glutamine 100X, 1% penicillin/streptomycin 100X. 
The three cell lines were grown as monolayer culture at 37°C in 5% CO2 and 95% humidity. 
 
 
RNA extraction and reverse transcription-qPCR 
 
Total RNA was extracted by using Tri-Reagent Kit according to manufacturer’s instructions. 
Briefly, cells were lysed with the reagent, chloroform was added and cellular RNA was 
precipitated by isopropyl alcohol. After washing with 75% ethanol, the RNA pellet was 
dissolved in nuclease-free water and stored at -80°C until further analysis. The total RNA 
concentration and the purity were assessed by spectrophotometric analysis in a Beckman 
DU730 spectrophotometer.  
The integrity of RNA was assessed on standard 1% agarose/formaldehyde gel. Total RNA 
(1µg) was reverse-transcribed using the iScript
TM
 cDNA Synthesis Kit according to 
manufacturer’s instructions and retrotranscription was performed using the iQ5
 TM
 Multicolor 
Real-Time Detection system (Bio-Rad Laboratories, Hercules, CA, USA) in agreement with 
the reaction protocol proposed by the manufacturer’s: 5 min at 25˚C (annealing), 45 min at 
42˚C (cDNA synthesis), and 5 min at 85˚C (enzyme denaturation).  
Real Time quantitative PCR was performed using the iQ5
 TM
 Multicolor Real-Time Detection 
system (Bio-Rad Laboratories, Hercules, CA, USA). All primers pairs were synthesized by 
Sigma-Aldrich (Sigma-Aldrich 3050 Spruce St. St. Louis, MO 63103) and were designed 
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using the software Beacon Designer 7.91 (PREMIER Biosoft International, Palo Alto, CA 
USA), β-actin and 18S were used as reference genes [360] (Table 1). 
PCR amplification was carried out in 25µL reaction volume containing 25ng of cDNA, 1x iQ 
SYBR Green Supermix [100 mM KCl; 40mM Tris–HCl, pH 8.4; 0.4mM each dNTP; 
50U/mL iTaq DNA polymerase; 6mM MgCl2; SYBR Green I; 20nM fluorescein; and 
stabilizers] and 250nM gene specific sense and anti-sense primers and 100nM primers for 
18S. All real-time PCR reactions were performed in triplicate using the three-step PCR 
program shown in Table 2. 
Standard curves using a “calibrator” cDNA (chosen among the cDNA samples) were prepared 
for each target and reference gene. In order to verify the specificity of the amplification, a 
melt-curve analysis was performed, immediately after the amplification protocol. Non-
specific products of PCR were not found in any case. The relative quantification was made 
using the Pfaffl modification of the ∆∆Ct equation, taking into account the efficiencies of 
individual genes. The results were normalized to 18S and beta-actin, the initial amount of the 
template of each sample was determined as relative expression versus one of the samples 
chosen as reference (in this case the control sample) which is considered the 1x sample.  
The data were analyzed using iQ5
TM 
optical system software version 2.0 (Bio-Rad 
Laboratories, Hercules, CA, USA). 
 
 
Total protein extraction  
 
After the Doxorubicin (Dox) treatment cells were washed twice with cold PBS and than lysed 
with 400µL of Cell Lysis Buffer (10X) and maintained on ice for 5 min. The cells were then 
scraped and sonicated briefly (3 pulses of 5s at 10W) using a sonicator UW3100 (Bandelin 
electronics, Berlin). The extracts were centrifuged at 14000 x g for 10 min at 4°C. The 
supernatant was collected for protein quantification by reaction with Bicinchoninic Acid 
Solution-KIT [361] according to manufacturer’s instructions. 
 
 
Preparation of crude membranes 
 
After the incubation cells were washed twice with cold PBS, treated with 5mL of a PBS 
solution 2mM EDTA, 200µM Phenylmethylsulfonyl Fluoride and scraped. 
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The cells were collected and centrifuged in 4°C at 1000 g for 5 min. The pellets were lysed by 
agitation for 40 min on ice with an hypotonic solution 1mM Sodium bicarbonate pH 7.4, 
sonicated  with 10 pulses of 5 sec at 10W (UW3100 sonicator, Bandelin electronics, Berlin) 
and centrifuged for 1h at 33000 rpm at 4°C. 
The resulting membrane pellets were resuspended with 300-400µL of 250mM sucrose, 10mM 
Hepes pH 7.4 and homogenized. The supernatant was collected for protein quantification by 
reaction with Bicinchoninic Acid Solution-KIT [361] according to manufacturer’s 
instructions. 
 
 
MTT assay 
 
The cell viability in terms of mitochondrial activity was determined by the MTT assay 
[362,363]. Typically the cells were cultured in a 6 multiwell plate. After the treatment the cell 
culture medium was removed the wells were washed with a 9.6g/L solution of PBS pH 7.2-
7.6. 50µL of a MTT stock dye solution (5mg/ml in PBS) was added to each well containing 
450µL of fresh medium. The plates were incubated at 37 °C under 5% CO2 for 1h. The 
medium from each well was removed and 500µL of DMSO (Sigma-Aldrich D5879-L) were 
added to dissolve the purple formazan crystals. The plates were shaken for 10min and the 
absorbance for each well was read on microplate reader (Beckman Coulter LD 400C 
Luminescence detector) at 570nm. The fractional absorbance was calculated by the following 
formula: % Cell survival = (mean absorbance in test well)/(mean absorbance in control wells) 
* 100 as described by Chearwae and coll. [364,365]. 
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Table 3. Seeding density for each cell line. 
TASK 1. MULTIDRUG RESISTANCE IN HEPATOCELLULAR CARCINOMA 
 
 
LC50 determination and MTT assay 
 
A 24 multiwell plate for each cell line was prepared seeding 40000 cells/cm
2
, cells were 
incubated at 37°C under 5% CO2 for 24h and then treated for 24 and 48h with different 
concentrations of Dox 0.5-1-5-15-30-60-120µM. 
The cell viability in terms of mitochondrial activity in each well was determined by the MTT 
assay [362,363] as previously described. Dox dose-response curve was plotted with 
SigmaPlot version 11 [366] the LC50 (the drug concentration where 50% of cells die) was 
calculated for each experiment based on the best curve fit. From each curve equation the 
value of the LC50 was extrapolated. With the same equation the experimental drug 
concentrations were selected in order to kill approximately 30% of the cells (LC30). 
 
 
Drug treatments  
 
The cells were seeded at the proper density (Table 3) and 
incubated at 37°C in a 5% CO2 incubator overnight. The 
day after the three cell lines were treated with their 
respective LC30 (2µM for IHH, 1µM for HuH7, 3µM for 
JHH6). In control samples Dox was substituted with the 
same amount of physiological solution. After 24h and 48h 
the total RNA, total proteins and crude membrane proteins 
were extracted as previously described. 
 
 
SDS-page Western Blot analysis 
 
Total proteins (10µg for IHH and JHH6; 50µg for Huh7) and crude membrane proteins (5µg 
for IHH and JHH6; 15µg for Huh7) were solubilised in Laemmli Buffer 5X and 10% β-
mercaptoethanol, separated with 10% SDS/PAGE gel and transferred to nitrocellulose 
Cell line Seeding density  
  
IHH 40000 cell/cm
2 
HuH7 40000 cell/cm
2 
JHH6 30000 cell/cm
2 
 
Meterials & Methods 
 
41 
 
Table 4.  Specific antibodies used for the SDS-page Western Blot analysis. 
membranes by electroblotting, using 25mM Tris Base, 192mM glycine, 20% methanol as 
transfer solution. 
After the transfer the membranes were blocked for 1h in 4% bovine milk/bovine serum 
albumin in TTBS (100mMTris Base, 2.5M NaCl, TWEEN 20 1%  pH 7.5). Subsequently the 
membranes were incubated overnight at 4°C with the respective primary antibodies in 
blocking solution at the dilution reported in Table 4. After washing 3 times for 10 min in 
blocking solution, immune-complexes were detected with the respective secondary antibodies 
after 60 min incubation (Table 4). 
Latter, membranes were washed (3 x 5 min Blocking solution, 1 x 5 min T-TBS 1 x 5 min 
TBS) and the bands were visualizated using Luminata
TM
 Western HRP substrate by following 
the manufacturer’s protocol. 
 
Protein 
Blocking          
Solution 
Primary 
Antibody 
Dilution 
Secondary 
Antibody 
Dilution 
      
ABCB1 Milk in T-TBS C219 1:100 anti-mouse 1:4000 
ABCC1 Milk in T-TBS A23 1:600 anti-rabbit 1:2000 
ABCG2 BSA in T-TBS BXP-53 1:100 anti-rat 1:6000 
ACTIN Milk in T-TBS A2066 1:4000 anti-rabbit 1:4000 
 
 
Fluorescence microscopy  
 
The cells were allowed to grow on glass coverslips, after the drug treatment cells were fixed 
with paraformaldehyde 3% in PBS for 20 min at room temperature(RT), they were washed 
twice with PBS, blocked for 2h at RTwith blocking solution (PBS, 5% v/v Normal Goat 
Serum, 1% w/v Bovine Serum Albumin, 0,3% v/v TritonX100) and incubated for 10 min at 
RT with Hoechst H33258 stain solution, washed twice with PBS and once with water, 
mounted and analysed under a fluorescence microscope (Leica DM2000, Wetzlar Germany). 
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Confocal analysis  
 
JHH6 cells were treated with 3µM of Dox. Confocal images were acquired with Nikon C1 
laser scanning confocal microscope (Nikon D-eclipse C1Si, Japan) with 100_/1.49 oil Apo 
TIRF objective (Nikon, Japan) at different time points (10min and 1h). The fluorophore 
excitation was performed with an air-cooled argon laser at 488 nm and appropriate filter sets 
were used to collect the fluorescence emission. Images were acquired and analyzed using the 
Nikon provided operation EZ-C1 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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         Figure 1. siRNA designed. 
TASK 2. TELOMERASE SILENCING EFFECTS IN HCC 
 
 
Tissue samples screening  
 
From the same diseased liver three samples were collected: tumoral (neoplastic lesion), 
pheripheral (lesion surrounding tissue) and distal. A total of 57 HCC samples (21 tumoral, 18 
peripheral, 18 distal) and 11 non tumoral liver samples were collected from Cattinara Hospital 
in Trieste. Tissues were homogenized, total RNA was extracted and reverse transcription-
qPCR was performed as previously described. 
  
 
siRNA design 
 
Homo sapiens telomerase reverse transcriptase (hTERT) 
transcript variant 1 (NM_198253.2) and 2 
(NM_001193376.1) mRNA sequence were obtained from 
Nucleotide database (www.ncbi.nlm.nih.gov). Predicted 
mRNA secondary structure were obtained by using mfold 
Web server version 2.3 [367] and UNAfold Software 
[368]. 
siRNA against Telomerase were designed using SiDE 
[369], siRNA Target Finder [370], BLOCK-iT
TM
 RNAi 
Designer (Invitrogen, Life Technologies Corporation, 
Grand Island, NY), DEQOR [371]. The best output 
sequences were manually mapped in the predicted mRNA 
secondary structure. Only the antisense sequences 
targeting 3’- and 5’-loop and loop structures where 
proceeded for further analysis. 
There were selected four siRNA sequences, one of them 
(SirTel 1) was manually modified to create the final siRNA sequence reported in Fig. 1A. The 
siRNA was synthesized by Sigma-Aldrich (Sigma-Aldrich 3050 Spruce St. St. Louis, MO 
63103). The remaining siRNAs (SirTel 2, SirTel 3 and SirTel 4) (Fig. 1B) were synthesized 
with  Silencer® siRNA Construction Kit according to manufacturer’s instructions.  
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Silencing experiments 
 
siLentFect toxicity 
 
In order to evaluate siLentFect Lipid Reagent for RNAi toxicity the day before transfection, 
JHH6 cell were seeded (9x10
3
 cells/cm
2
) in a  24-well plates in serum-containing William’s E 
medium. The cells were incubated at 37°C in a 5% CO2 incubator overnight. Sixty minutes 
prior to transfection, medium from each well was carefully removed and replaced with 250µL 
of fresh growth medium. Different concentrations of siLentFect Lipid Reagent for RNAi (0- 
0.25-0.5- 1- 1.25-1.5-1.75µL) were added to 250µL of serum-free William’s E medium and 
then dispensed into the wells (total volume 0.5mL). After 72h cell viability was determined 
by the MTT assay [362,363] as described previously. All experiments were performed in 
triplicate. 
 
 
Silencing 
 
The day before transfection, JHH6 cell were seeded (9x10
3
 cells/cm
2
) in a 6-well plate in 
serum-containing William’s E medium.  Sixty minutes prior to transfection, medium from the 
wells was carefully aspirated and replaced with 1mL of fresh growth medium to each well. 
For each well to be transfected, 500µL of serum-free medium containing 1.2µL of siLentFect 
Lipid Reagent for RNAi and 500µL of serum-free medium containing siRNA (final 
concentration 100, 200, 400nM) were prepared. The diluted siRNA and the diluted siLentFect 
were mixed and incubated at RT for 20 min (final volume 1mL). The complexes were directly 
added to cells in serum-containing medium (final volume 2mL; final siRNA concentration 25, 
50, 100nM). In each plate three controls were included: cells -siRNA/- siLentFect; cells -
siRNA/+siLentFect; cells +siRNA/-siLentFect. The plate was incubated at 37°C in a 5% CO2 
incubator for 72h. All experiments were performed in triplicate for all the four siRNAs 
designed. After 72h silenced cells were harvested, the total RNA was extracted using Tri-
Reagent Kit according to manufacturer’s instructions (see general procedures section) and 
reverse transcription-qPCR was performed as previously described. 
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Fitch conjugation transfection efficiency 
 
To 5µg of siRNA were added 1.5 volumes of nuclease-free water, 1 volume of sodium 
bicarbonate 1.2M, 2 volume of FITC solution 40mM. The mixture was incubated at RT for 
24h in the dark with  occasional vortexing. The labelled siRNA was precipitated overnight at  
-20°C by adding 1/10volume of sodium acetate 3M pH 5.2 and 2 volumes of absolute ethanol. 
The mixture was centrifuged at 8000g for 15 min at 4°C and washed with 70% ethanol. The 
pellet was dried at RT and then resuspended in nuclease-free water. 
The base/FITC ratio was calculated by spectrophotometric analysis in a Beckman DU730 
spectrophotometer. 
JHH6 cells were silenced with 25nM and 100nM of FITC labelled siRNA as mentioned 
before. Cells were analysed 24h, 48h  and 72h post-transfection with Nikon C1 laser scanning 
confocal microscope (Nikon D-eclipse C1Si, Japan) with 100/1.49 oil Apo TIRF objective 
(Nikon, Japan). The fluorophore excitation was performed with an air-cooled argon laser at 
488 nm and appropriate filter sets were used to collect the fluorescence emission. Images 
were acquired and analyzed using the Nikon provided operation EZ-C1 software.  
FITC intracellular fluorescence was also determined by flow cytofluorimetry using a Becton 
Dickinson FACSCalibur System, following excitation with an argon ion laser source at 488 
nm and appropriate filter sets. Data were collected in 10,000 cells and analyzed using 
Cellquest software from BD Biosciences (San Jose, CA, USA).  
 
 
Silenced fibroblast viability  
 
Fibroblast primary cell culture was used as a telomerase negative control for the silencing 
experiments. Primary fibroblasts cultures were obtained from human healthy donors. Cells 
were cultured in RPMI 1680 medium with 10% (v/v) FBS, 1% L-glutamine 100X, 1% 
penicillin/streptomycin 100X. The day before transfection, fibroblasts were seeded (3x10
4
 
cells/cm
2
) in a 6-well plate in serum-containing RPMI 1680 medium. 
The cells were incubated overnight. Cells were treated with 25-50-100nM of SirTel 1 
following the same procedure used for JHH6 cells. Control cells without treatment were 
included into analysis. After 72h of incubation  cell viability was determined by the MTT 
assay [362,363] as previously described. 
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TRAP 
 
The day before transfection, JHH6 cell and human primary fibroblasts were seeded (9x10
3
 
cells/cm
2
) in a 6-well plate. The cells were transfected with 25nM of SirTel 1 as mentioned 
before. After 72h telomerase activity was assessed using TRAPeze® kit (Millipore 
Corporation, Billerica, MA) according to manufacturer’s instructions.  
 
 
Time course experiments  
 
The day before transfection, JHH6 cell were seeded (9x10
3
 cells/cm
2
) in a 6-well plate in 
serum-containing William’s E medium. The cells were transfected with 25nM of SirTel 1 as 
previously described. The hTERT and albumin mRNA expression was followed in time by 
quantitative Real time PCR at 24-48-72-96-120-168-216-264-312h post-treatment. 
In re-exposure experiments silenced cells were re-exposed at 72h with 25nM of SirTel 1, 
hTERT expression was followed in time by quantitative Real time PCR at 120-168-216-264h 
post-treatment. 
 
 
SirTel-1 vs. Dox cell viability  
 
The day before transfection, JHH6 were seeded (9x10
3
 cells/cm
2
) in a 6-well plate in serum-
containing William’s E medium. 
The cells were incubated at 37°C in a 5% CO2 incubator overnight. Cells were silenced either 
with 25-50-100nM of SirTel 1 either with 25-50-100nM Dox as previously described. Control 
cells without treatment were included into analysis. After 72h of incubation cell viability was 
determined by the MTT assay [362,363] as previously described. 
 
 
Cell cycle FACS analysis 
 
After 72h, silenced cells were detached, pelleted, washed twice with PBS and then 
resuspended in 500µL PBS. With a glass Pasteur pipet the cells were homogenized in order to 
disaggregate the eventual groups of cells for obtaining a single cell suspension, subsequently 
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they were  transferred to a fresh tube containing 4.5mL of ethanol 70%. Fixed cells were 
pelleted, to remove the ethanol, and resuspended  in 1mL of staining solution (0.1% v/v 
TritonX-100 in PBS; 0.02 mg/mL PI; 0.2 mg/mL RNAse A). After 30 min of RT incubation, 
cellular DNA content was measured by flow cytofluorimetry using a Becton Dickinson 
FACSCalibur System, following excitation with an argon ion laser source at 488nm and 
appropriate filter sets. Data were collected in 10,000 cells and analyzed using Cellquest 
software from BD Biosciences (San Jose, CA, USA). The percentage of cells in G0/G1, S and 
G2/M was determined from DNA content histograms. 
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RESULTS 
 
TASK 1. MULTIDRUG RESISTANCE IN HEPATOCELLULAR CARCINOMA 
 
 
ABCs basal mRNA expression levels 
 
Our in vitro model for studying the role of 
ABC transporters in MDR in HCC 
comprehends three hepatic cell lines: IHH 
(immortalized hepatocytes, non tumoral 
control), HuH7 (well differentiated 
hepatocyte derived cellular carcinoma cell 
line), in spite of the tumoral origin of this 
cell line, some of the main hepatocyte’s 
characteristics are conserved (albumin 
production), JHH6 (poorly differentiated 
hepatocytes derived cellular carcinoma cell line). The basal mRNA expression levels of 
ABCB1, ABCC1 and ABCG2 were assessed in all the three cell lines and are reported in 
Figure 1. ABCB1 is mainly expressed in Huh7 cells which have also the lowest ABCC1 
expression in comparison with IHH and JHH6. ABCG2 mRNA expression is inversely 
correlated with the differentiation grade of the cells. 
 
 
Drug treatments and LC50 determination  
 
In order to establish the cellular sensitivity to Dox 
viability/dose (0.5-1-5-15-30-60-120µM) curves 
were plotted for each cell line under study and the 
lethal dose 50 (LC50) was calculated for each 
experiment based on the best curve fit. From each 
curve equation the value of the LC50 was 
extrapolated (Table 1). With the same equation the experimental drug concentrations were 
selected in order to kill approximately 30% of the cells (LC30) (Table 1). 
Cells LC50 µM 
S.D. (24h) 
Exp. concentrations 
(LC30 µM)  
IHH 4.5±0.3 2.0 
Huh7 4.3±0.3 1.0 
JHH6 4.5±0.8 3.0 
Figure 1. ABCs basal mRNA expression levels. 
ABCB1                 ABCC1                  ABCG2  
Table 1. LC50 and Dox experimental concentrations. 
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Figure 2. nuclear Dox accumulation  and 
morphological changes. 
(A) Flourescence microscopy image of JHH6 cells 
treated with 3µM of Dox. (left) Cell nuclei are 
stained with hoescht (blue), (right) nuclei 
containing Dox. (B) Bright field microscopy of 
control JHH6 cells and treated cells (C), red arrows 
indicate multinucleated cells or apoptotic cells. 
   Table 2. ABCB1 and ABCG2 mRNA expression. 
Dox cellular uptake and induced damages 
 
Dox fluorescent properties (lex.470nm lem. 585nm) 
allow to detect its presence within the cell.  
Confocal analysis revealed that JHH6 cells treated 
with 3µM of Dox showed a nuclear Dox staining 
evident after 10 min (data not shown). 
For the fluorescence microscopical analysis cells 
were exposed at their respective experimental Dox 
concentration. The cell nuclei were stained with 
Hoechst. After 24h was evident a co-localization of 
Dox and Hoechst denoting the nuclear drug 
accumulation. After 48h morphological alterations 
were evident denoting a marked cell damage (Fig. 
2). After Dox exposure bright field microscopy 
analysis leaded to the identification of altered 
cellular shapes with unequal cell size (35-345µm) 
and unclear cellular profile (Fig. 2C). Moreover 
multinuclear cells were also observed. These 
features contrast with the normal cell morphology 
with fusiform shapes, homogeneous and well-
distributed sizes (35-55µm) and distinct 
boundaries (Fig. 2B). 
 
 
ABC mRNA and protein expression in IHH cells  
 
IHH cells were exposed to 2µM of Dox for 24h 
and 48h. ABCC1 mRNA expression significantly 
decreases both at 24h (p<0.05) and 48h (p<0.001) 
(Fig. 3B). 
ABCC1 protein expression significantly decreases 
only after 48h Dox exposure (p<0.05) (Fig. 3B). 
ABC 
protein 
Time Folds of relative 
expression vs. ctrl 
ABCB1 24h 15.01±1.69 (p<0.001) 
 48h 13.28±2.18 (p<0.001) 
ABCG2 24h 4.72±1.08 (p<0.01) 
 
48h 3.51±1.53 (p<0.05) 
A 
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Figure 3. ABCC1 mRNA and protein expression in IHH cells. 
ABCB1 and ABCG2 proteins were undetectable by SDS-page western blot due to their very 
low expression levels, consequently the analysis was performed only at mRNA level (Table 
2). Both ABCB1 and ABCG2 mRNA expression significantly increases after 24h (p<0.001 
and p<0.05 respectively). After 48h the mRNA expression remains significantly higher when 
compared with controls for both genes (p<0.001 and p<0.01 respectively), although there is a 
trend of decrease both cases. Results are expressed as mean ±S.D. from 3 independent 
samples and statistical analysis was performed using the Wilcoxon-Mann-Whitney test. 
 
 
 
 
 
 
 
 
 
ABC mRNA and protein expression in Huh7 cells  
 
HuH7 cells were treated with 1µM of Dox for 24h and 48h. ABCB1 mRNA expression 
significantly increases at 24h (p<0.001) before restoring the basal levels after 48h. Protein 
expression significantly increases only after 48h (p<0.05) (Fig. 4A). Regarding ABCC1 
mRNA expression significantly decreases both at 24h (p<0.001) and 48h (p<0.001), on the 
contrary protein levels increases after 24h (p<0.05) and remain higher also at 48h (p<0.05) 
(Fig. 4A). For ABCG2 mRNA expression significantly increases at 24h (p<0.001) before 
returning to basal levels after 48h. There is a ABCG2 protein downregulation  which reaches 
the maximum at 48h (p<0.001) (Fig. 4A). Results are expressed as mean ± S.D. from 3 
independent samples and statistical analysis was performed using the Wilcoxon-Mann-
Whitney test. 
 
 
A B 
(A) Representative western blot of ABCC1 at 24h 
and 48h vs. controls (ctrl). 10µg of total protein 
and 5µg of membrane protein extracts were 
loaded. The row indicates the ABCC1 
corresponding band at the predicted molecular 
weight. (B) ABCC1 mRNA and protein relative 
expression. mRNA levels  (red line) are reported as 
folds of expression vs.β-actin/18S. Protein 
expression (blue line) was normalized to actin. 
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Figure 4. ABCs mRNA and protein expression in HuH7 cells. 
 
(A) ABCB1, ABCC1 and ABCG2 mRNA and protein relative expression. mRNA levels (red lines) are reported as folds of 
expression vs.β-actin/18S. Protein expression (blue lines) was normalized to actin. (B) representative western blot  24h 
and 48h vs. controls (ctrl). 30µg, 50µg and 60µg of total protein extracts were loaded for ABCB1, ABCC1 and ABCG2 
detection respectively. The black rows indicates corresponding band at the predicted molecular weight for each ABC 
protein. 
Table 3. ABCB1 mRNA expression. 
 
 
 
ABC mRNA and protein expression in JHH6 cells  
 
JHH6 cells were treated with 3µM of Dox for 24h 
and 48h. ABCB1 protein expression was 
undetectable by SDS-page western blot due to the 
very low expression level consequently only mRNA 
expression data are available (Table 3). ABCB1 
mRNA levels significantly increase after 24h 
(p<0.001) as well as after 48h treatment (p<0.001). ABCC1 mRNA expression in JHH6 cells 
significantly decreases both at 24h (p<0.01) and 48h (p<0.001). On the contrary ABCC1 
protein expression increases at both times, although its values does not reach significant (Fig. 
5). ABCG2 mRNA expression decreases at both experimental times being significant only at 
48h (p<0.001). On the contrary the protein expression increases both at 24h and 48h being 
significant only at 24h (p<0.001) (Fig. 5). Results are expressed as mean ±S.D. from 3 
independent experiments and statistical analysis was performed using the Wilcoxon-Mann-
Whitney test. 
ABC 
protein 
Time Folds of relative 
expression vs. ctrl 
ABCB1 24h 8.71±1.28 (p<0.001) 
 48h 30.28±0.04 (p<0.001) 
A 
B 
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Figure 5. ABCs mRNA and protein expression in JHH6 cells. 
(A) ABCC1 and ABCG2 mRNA and protein relative expression. mRNA levels (red lines) are reported as folds of expression 
vs.β-actin/18S. Protein expression (blue lines) was normalized to actin. (B) Representative western Blot 24h and 48h vs. 
controls (ctrl). 10µg and 50µg of total protein extracts were loaded for ABCB1 and ABCG2 detection respectively. The 
black rows indicates corresponding band at the predicted molecular weight for each ABC protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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 Figure 6. Liver cancer sampling. 
TASK 2. TELOMERASE SILENCING EFFECTS IN HCC 
 
 
This study is part of a macro-project whose main objective is to use a liver specific delivery 
system to  target tumoral genes. In particular the aim of this section is to selectively silence a 
cancer related and specific gene in HCC. Gene silencing could represent a future alternative 
for cancer treatments as an alternative of chemotherapy.  
 
 
Target selection 
 
Based on literature, a set of 4 genes (aurora kinase A, midkine, survivin and telomerase) was 
selected as possible candidates for gene silencing. The selection criteria taken into 
consideration were that the target gene should: 
  Be essential for cancer cell survival, growing and  maintenance. 
  Be over-expressed or exclusively expressed in tumoral 
cells. 
 Be involved in as less pathways as possible. 
For each gene the mRNA expression was assessed in human 
HCC derived samples (n=22 tumoral, n=18 peripheral and 
n=18 distal; see Figure 6 for details) as well as in normal liver 
(n=11). 
Aurora kinase A resulted upregulated in tumoral samples 
although its levels did not reach the significance (Fig. 7A). A very high midkine mRNA 
expression was observed in tumoral samples in comparison with controls (Fig. 7B). However 
there were no statistically significant differences among the considered groups due to the high 
standard deviations. Survivin was not differently expressed among controls, tumoral, 
peripheral and distal samples (Fig. 7C). In contrast with all the potential target genes under 
study, telomerase was not expressed in the eleven non-tumoral samples, moreover a 
statistically significant increased mRNA expression in the tumoral portion of the diseased 
liver compared with the peripheral (p<0.01) and the distal (p<0.001) ones was observed (Fig. 
7D). This results pointed to the conclusion that telomerase would represent the appropriate 
gene since is exclusively expressed in the tumoral portions, with no detectable levels in 
healthy tissue. For this reason, the following experiments include this gene.  
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mRNA levels are reported as folds of expression vs.β-actin/18S.  For (A) aurora kinase A, (B) midkine and (C) surviving the 
expression in tumoral, peripheral and distal samples is reported in relation to the non-tumoral samples. (D) Telomerase 
tumoral and peripheral mRNA expression is reported as relative to the distal samples.  
 
 
 
 
siRNA design 
 
The siRNAs against telomerase were disegned on the catalytic subunit of the enzyme 
(hTERT) which is the activity rate limiting subunit. The siRNAs were designed in the 
homology region of the two known hTERT mRNA sequences (NM_001193376.1; 
NM_198253.2). 
For the  design the siRNAs were taken into consideration both sequence-based limitations 
(siRNA and mRNA) [369,372-375] and structure-based limitations (target mRNA) [376,377]. 
siRNA sequence-based limitations are: 
 Figure 7. mRNA relative expression in HCC human samples. 
A B 
C D 
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             Figure 8. mRNA secondary structures. 
- G/C 36-53%  
- base at 5' AS(antisense strand) should be A/U  
- base 13-19 AS A/U at least 3/4  
- base 16 AS A/U  
- base 1 at 5' SS G/C  
- avoid  AAAA TTTT GGG/CCC motifs and GCs 
stretches  
- G/C  region 13-19  <19%  2-12 ~ 52%  
- ∆G Kcal/mol at 5'-AS terminal, region 9-14 less 
than -8,5  
- no ∆G < 13 Kcal/mol in region 7-12  
 
mRNA sequence-based limitations are: 
- avoid 3’ UTR or 5’ UTR 
- avoid regions closer to STOP codons, and splicing sites  
- keep 75nt distance from the start site 
- avoid AAAA TTTT GGG/CCC motifs and GCs stretches 
 
Based on these consideration of the 
sequence-based rules, siRNAs were 
designed using free web tools such as 
RNAi Target Sequence Selector, 
BLOCK-iT
TM
 RNAi designer, SIDE, 
Deqor, siRNA Target Finder. There is 
evidence that target’s secondary 
structures can influence silencing 
efficiency [376,377]. For instance, 
mRNA secondary structures such as 
stem and loop derived structures can 
influence accessibility of the siRNA to 
the target, siRNA/mRNA annealing and 
duplex stability (Fig. 8). In particular 
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Figure 9. SirTel 1 features. 
(A) ss targeting a loop structure in the hTERT mRNA (NM_198253.2). (B)  
SirTel 1 double strand siRNA with two DNA base at the 3’ end of the ss 
(red circle). The expected Dicer cutting is also shown. 
 
Table 4. siRNA features. 
central loops and stem structures seem to inhibit the silencing efficacy [376,377]. For these 
reasons the target mRNA sequence was folded using mFold, a web server tool for nucleic acid 
folding (http://mfold.rna.albany.edu/?q=mfold/ RNA-Folding-Form) and UNA-fold, a 
software for nucleic acid folding and hybridization. The target sequence was fractioned in 800 
bases strings with each one with 200 bases of overlap. The strings were folded as well as the 
whole sequence. Only the secondary structures that were conserved in both string and whole 
sequence were considered suitable siRNA target regions. 
All the siRNAs selected using 
the web tools mentioned above 
were manually alligned to the 
secondary target structure. Only 
one sequence, targeting a loop 
structure (Fig. 9A), was selected 
for further modifications such as 
the addition of two DNA bases 
at 3’end of the sense strand (ss) 
and a 3’ overhang of the 
antisense strand (as) to became 
a direct Dicer substrate (Fig. 9B). Dicer is a RNase III class endonuclease which in vivo cuts 
long dsRNA involved in the RNAi pathways [378]. The siRNA designed was called SirTel 1 
and synthetized by Sigma-Aldrich, St.Louis, MO. 
Other three siRNAs were designed not following the rules mentioned above due to the 
restrictions imposed by the kit used for the synthesis (Silencer® siRNA Construction Kit; 
Ambion, Invitrogen, Life Technologies Corporation, Grand Island, NY). The three siRNAs 
are reported in Table 4. 
 
siRNA 
Name 
siRNA sequence 
Programs used for siRNA 
identification 
Targeting 
structure 
Position in the seq. 
NM_198255.2 
SirTel 2 
 
RNAi Target Sequence Selector 3’ loop 3154-72 
SirTel 3 
 
siRNA Target Finder; 
BLOCK-iTTM RNAi designer 
stem 3265-83 
SirTel 4 
 
Deqor stem 434-51 
A B 
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Table 5. Sample organization and controls included in the experimental set-up. 
Choice of in vitro cell model 
 
 
The first approach for selecting a suitable cell model 
was to assess hTERT expression in several hepatic 
cell lines like human immortalized hepatocytes 
(IHH) and in three different HCC derived cell lines 
with various stages of differentiation Huh7, HepG2 
(moderately differentiated HCC derived cells) and 
JHH6 (poorly differentiated HCC derived cell line).  
From the data reported in Figure 10, is possible to 
conclude that the hTERT mRNA expression is 
higher in the most undifferentiated cell line, 
whereas in IHH its expression is minimal. 
It worth to be noticed that the IHH cell line 
constitute a non tumoral cell line, however they 
express telomerase since they were immortalized with a SV40 viral derived construct 
containing telomerase gene. All together these results point to the conclusion that JHH6 
constitute a valid model for the hTERT silencing, and for this reason this cell line will be used 
for the future experiments. Results are expressed as mean ± S.D. from at least 3 independent 
samples and statistical analysis was performed using the Tukey-Kramer Multiple 
Comparisons Test. 
 
 
Setting-up the working conditions 
 
siLenFect toxicity, siRNA 
working concentrations and 
silencing timing were evaluated 
in preliminary setting-up 
experiments (data not shown). 
The following working 
conditions were chosen: 
0.8µL/mL of siLenFect and 25, 
50, 100nM of siRNA for 72h silencing. For each experiment three controls were included 
 
Cells 
9000 cells/cm2 
siLentFect 
0.8µL/mL 
 
siRNA 
25nM, 50nM, 100nM 
 
Ctrl    
Ctrl vehicle    
Ctrl siRNA    
Treated cells    
Figure 10. hTERT mRNA relative expression in 
different cell lines. 
mRNA levels are reported as folds of expression 
vs. β-actin/18S. hTERT mRNA expression is 
reported as relative to IHH cells. 
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Figure 11. Proinflammatory cytokines mRNA relative expression. 
(Table 5). There was no statistically significant difference in cell viability among the control 
and cells treated with 0.8µL/mL of siLenFect (data not shown). Transfection efficiency was 
calculated  by Flow cytometry using FITCH conjugated siRNA and it was higher than 75%. 
 
 
Cytokines mRNA expression  
 
JHH6 were transfected with 25, 50 and 100nM of SirTel 1, SirTel2, SirTel 3 and SirTel 4 and 
after 72 hours proinflammatory cytokines mRNA expression was assessed (Fig. 11).  
 
 
 
 
It was observed an overall significant increased mRNA expression after SirTel 2, SirTel 3 and 
SirTel 4 transfection at every considered concentration. SirTel 1 only induced a significant 
increased TNFα mRNA expression at 25nM concentration (p<0.05) (Fig. 11). As expected the 
vehicle and the siRNAs alone have no effect in modulating TNFα, IL6 and IL8 mRNA 
expression. Results are expressed as mean ±S.D. from 3 independent samples and statistical 
analysis was performed using the Wilcoxon-Mann-Whitney test. 
 
 
mRNA levels are reported as folds of expression vs.β-
actin/18S. All the data are expressed in relation to Ctrl.  
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Figure 12. hTERT mRNA relative expression in JHH6 cells  
Telomerase silencing 
 
Telomerase mRNA expression was assessed in JHH6 cells after 72h of SirTel 1, 
SirTel2, SirTel 3 and SirTel 4 transfection (Fig. 12). 
 
 
 
 
 
SirTel 1 and Sirtel 4 significantly reduce the hTERT mRNA expression after 72h silencing at 
all the considered concentrations (p<0.001). SirTel 2 had a silencing effect limited to higher 
doses, 50nM and 100nm (p<0.05). The silencing effect of SirTel 3 is inversely correlated with 
its concentrations, indeed the higher silencing effect was assessed at 25nM (p<0.001). At 
50nM the decrease in the mRNA expression is still significant (p<0.01) whereas at 100nM 
there was no more statistically significant difference among the control and the treated 
sample. 
All together these data show that there is non statistically significant difference in hTERT 
mRNA expression among the three controls considered. Moreover SirTel 1, SirTel 2 and 
mRNA levels are reported as folds of expression vs.β-actin/18S.  All the data are expressed in relation to Ctrls.  
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Figure 13. Cell viability in siRNA treated primary fibroblasts. 
SirTel 4 have a dose dependent silencing effect. However due to the low silencing effect, 
SirTel 2 and SirTel 3 were excluded for the future determinations.  
All the results are expressed as mean ±S.D. from 3 independent samples and statistical 
analysis was performed using the Wilcoxon-Mann-Whitney test. 
 
 
Off-target effects assessment 
 
After few years from the siRNA discovery, it became evident that sometimes siRNAs can 
cross-react with other unspecific mRNA different from their target (off-target) causing, in this 
way, undesired effects [379]. To evaluate the off-target effect of SirTel 1 and SirTel 4, 
fibroblast primary cultures were silenced since fibroblasts do not express telomerase. The 
presence of off-target effect was evaluated in terms of cell viability (Fig. 13).  
 
 
In cells treated with SirTel 1 the variation in cell viability was due to the vehicle by itself, as a 
matter of fact there was no significant difference between the vehicle control and the treated 
samples. On the contrary SirTel 4 caused a dose dependent reduction in cell viability which 
resulted significantly considerable in respect of the vehicle control (p<0.01 for 100nM of 
siRNA). Results are expressed as mean ±S.D. from 3 independent samples and statistical 
analysis was performed using the Wilcoxon-Mann-Whitney test. 
Due to the intrinsic cell toxicity SirTel 4 was discarded. Only SirTel 1 was used for further 
experiments. 
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Telomerase enzymatic activity 
 
 JHH6 and human derived fibroblasts primary cultures were treated with 25 nM of SirTel 1 
for 72h. Protein lysates were collected and Telomeric Repeat Amplification Protocol (TRAP) 
was performed. Briefly, telomerase present in the lysates elongates oligonucleotides that 
mimic the telomeres ends. The products generated are then amplified by PCR. In the 
experiment telomerase heat inactivated samples were included. After hTERT silencing there 
was a statistically significant decrease in telomerase activity (p<0.001) (Fig. 14B). There was 
no telomerase activity in heat treated cells and in human primary fibroblasts (Fig. 14A). 
Results are expressed as mean ± S.D. from 3 independent samples and statistical analysis was 
performed using the Wilcoxon-Mann-Whitney test. 
 
 
 
 
 
 
 
A 
 
B 
 
Figure 14. Telomerase enzymatic activity. 
 
(A) PCR products of telomerase activity were loaded into a polyacrylamide gel (10%). J6C: control JHH6 cells; J6C-: heat 
treated control JHH6 cells; J6T: silenced JHH6 cells; J6T-: heat treated silenced JHH6 cells; FIB: human primary fibroblast; 
FIB-: heat treated primary fibroblasts. (B) Telomerase activity was expressed as relative total product generated (TPG) 
units. Data were normalized using an internal standard control.  
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Figure 15. mRNA hTERT relative expression: time course. 
Silencing time course 
 
JHH6 cells were treated with 
25nM on SirTel 1 and the hTERT 
mRNA expression was followed 
along time. hTERT mRNA 
downregulation reached its 
maximum after 72h treatment 
(Fig. 15). After 96h hTERT 
mRNA expression start to 
increase to restore the initial 
levels  at 312h after the treatment. 
Results are expressed as mean 
±S.D. from 3 independent samples 
and statistical analysis was 
performed using the unpaired t-
test. 
 
 
Investigating the hTERT silencing effects 
 
Cell morphology. The first evident effect after 72h of SirTel 1 transfection was a change in 
cell morphology. By observations with bright filed microscope was appreciated a change in 
JHH6 cell morphology from a fibroblastic-like shape to an hepatocyte-like shape (Fig. 16).  
 
  
 
 
 
mRNA levels are reported as folds of expression vs.β-actin/18S. All 
data are expressed in relation to the control (untreated cells).  
 
 
 
 
Figure 16. Optical images of JHH6 cells after 72h treatment 
Cells were observed under optical microscope (10X). (A)(B) Untreated cells at different confluences. (C)(D) Vehicle and 
siRNA controls respectively. (E)(F) Treated cells. 
A                                B      C         D          E            F 
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The alteration in cellular morphology was also observed by a Flow Cytometry analysis 
comparing the forward-side scatter plot of silenced cells vs. controls (Fig. 17). The forward-
side scatter plot gives information about the size and the internal complexity of the cells. 
After the hTERT silencing there was a change both in size and complexity of the cells. This is 
evident by the shift in the green cloud along the x and y axes in the plots reported in Figure 17 
compared to the control (red cloud).  
 
 
 
 
Figure 17. Forward-side scatter Plot of JHH6 cells after 72h silencing. 
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Albumin expression. The morphological 
chances of JHH6 were associated with an 
increase in the albumin mRNA expression. 
The albumin constitute an hepatic hallmark 
which is normally not express or express at 
very low levels in poorly differentiated JHH6 
cells. After hTERT silencing there was an 
increased albumin expression, although not 
significant, that corresponded to the minimum 
in the hTERT mRNA expression (Fig. 18).  
Results are expressed as mean ± S.D. from 3 
independent samples. 
 
Cell viability. The treatment for 72h with 25-
50-100nM of SirTel 1 induced a significant 
reduction in JHH6 cells viability (Fig. 19).  
Furthermore when compared with the toxic 
effect of the same amount of Dox, SirTel 1 
resulted more effective in reducing cell 
viability especially at lower concentrations 
with 63% of viable cells after 72h of 25nM 
siRNA vs. 85% of viable cells after 72h of 
25nM Dox exposure. Results are expressed as 
mean ±S.D. from 3 independent samples and 
statistical analysis was performed using the 
Wilcoxon-Mann-Whitney test. 
 
Cell cycle analysis. In order to assess the effect of SirTel 1 on the cell cycle, JHH6 were 
transfected with 25, 50 and 100nM of SirTel 1 for 72h and the DNA content of both treated 
cells and controls was analyzed by Flow Cytometry by propidium idodide DNA staining. 
During the analysis 10000 cells were counted and categorized as G1-, S- or G2/M-phase cells, 
based on DNA content. For the final analysis were considered only the cells that have the 
100% probability to be in each cell cycle phase. 
Figure 18. Time course of albumin vs. hTERT mRNA 
expression. 
mRNA levels are reported as folds of expression 
vs.β-actin/18S.  All the data are expressed in 
relation to the control (untreated cells).  
 
 
The data are expressed  in percentage of viable cells 
in relation to controls. For Dox treated cells the 
control was cells treated with  vehicle and for 
silenced cells the control was cells treated with the 
siLentFect (vehicle) only. 
 
    Figure 19. JHH6 cells viability after 72h treatment. 
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  Figure 21. JHH6 cells cycle analysis after hTERT silencing.  
The plot in Figure 20 shows the percentage of JHH6 cell at every cell cycle phase. There is no 
difference in cell distribution among the controls (Fig. 20A) while there is a shift in the profile 
of treated cells vs. controls (red line Fig. 20B). 
 
 
 
In silenced samples there was a statistically 
significant increase of G1 arrested cells 
(p<0.01), while there was a statistically 
significant decrease in S phase cells 
(p<0.05) for all the considered siRNA 
concentrations (Fig. 21). A decrease in G2 
phase cells resulted significant (p<0.05) 
only in cells treated with 100nM of siRNA. 
No statistically significant differences were 
observed among controls. Statistical 
analysis was performed using the 
Wilcoxon-Mann-Whitney test. 
Cell cycle representative Plot. The cells were harvested and analyzed with propidium iodide staining to assess cell cycle 
distribution by flow cytometry analysis and the results were expressed as mean ±S.D. of three independent experiments. 
(A) Overlay of cell cycle distributions of controls . (B) Overlay of cell cycle distributions of JHH6 cells exposed to different 
concentrations of SirTel 1. On the y-axes is reported the percentage of cells in each phase of the cell cycle. On the x-axes is 
reported the DNA content. 
Figure 20. Cell cycle phases JHH6 distribution. 
A 
 
B 
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JHH6 re-exposure to SirTel 1 
 
After 72h silencing with 25nM of SirTel 1 JHH6 cells were re-exposed to 25nM of the same 
siRNA and silencing was followed during the next 168 hours. Re-exposing the cells to 
additional 25nM of SirTel 1 caused a reduction of mRNA levels by 76% compared to the 
amount already present after the first treatment (Fig. 22). The statistically significant decrease 
(p<0.001) in the hTERT mRNA was maintained at least until 168h after the re-exposure.  
Results are expressed as mean ±S.D. from at least 3 independent samples and statistical 
analysis was performed using the unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
Blu line: hTERT mRNA expression time 
course after silencing. Red line: hTERT mRNA 
expression time course after re-exposure to 
25nM of SirTel 1. The red arrow indicates 
the time point of re-exposure. mRNA levels 
are reported as folds of expression vs.β-
actin/18S. All the data are expressed in 
relation to the control. 
 
Figure 22. Re-exposure to the siRNA. 
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DISCUSSION 
 
 
Hepatocellular Carcinoma (HCC) ranks fifth in frequency of cancers in the world and every 
year more than 700.000 people die of this disease.  
HCC usually arises in the setting of HCV and HBV infections, non-alcoholic steatohepatitis 
and cirrhosis which cause hepatic dysfunction that limits treatment options. 
Currently therapeutic guidelines are provided by the Barcelona Clinic Liver Cancer (BCLC) 
staging system. Orthotopic Liver Transplantation (OLT) or liver resection represent the best 
treatments for HCC. However, most patients cannot be subjected to potential curative OLT or 
resection because of extensive tumor involvement of the liver, metastasis, invasion of the 
portal vein or advanced underlying hepatocellular disease. Systemic chemotherapy or 
chemoembolization represent a palliative or down-staging alternative, but drug therapy of 
cancer is hampered by multidrug resistance (MDR). The establishment of the MDR leads to 
new therapeutically approaches such as gene therapy. 
To overcome the MDR phenomena we developed two parallel studies: 
- Multidrug resistance in HCC (TASK 1), in which we plan to clarify the role of ABC 
transporters in the development of MDR. 
- Gene therapy applied to HCC in which we plan to use a liver specific lipoprotein-based 
structures as delivery system to target hepatic cancer cells with siRNAs. Chemotherapy is 
considered a double edged sword, due to the numerous side effects of drug usage, and the 
use of siRNAs instead of drugs could represent a good down-staging therapy alternative, 
avoiding MDR establishment. In this thesis we focused the attention on the telomerase 
silencing effects in HCC (TASK 2), the developing of the delivery particle will be 
performed in the near future. 
 
Task 1: Multidrug resistance in HCC 
Since many years it has become evident the role of the ABC transporters in the MDR 
establishment [16,19,20]. Although ABCs are widely studied in many cancer types, there are 
contrasting and incomplete data regarding ABC expression and behavior in HCC. This is true 
especially for ABCG2 (also known as BCRP, breast cancer resistance protein) which is 
poorly studied in this kind of tumour. 
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The up-regulation of ABCs can compromise chemotherapy and influence therapy choices as a 
consequence studying the modulation of these transporters in response to Dox (the widely 
used antineoplastic drug) therapy could represent an important aid for conventional medicine. 
For our studies we considered three cellular models with distinct grade of differentiation: IHH 
cells (differentiated immortalized hepatocytes [380], HuH7 cells (moderately differentiated 
HCC derived cell line), JHH6 cells (poorly differentiated HCC derived cell line). Each cell 
line has a basal distinctive ABC expression pattern with the highest levels of ABCC1 and 
ABCG2 expression observed in the less differentiated cells (JHH6). Furthermore ABCB1 was 
exclusively expressed in HuH7 cells (Fig. 1 results section).  
When treating the cells with Dox doses lower than the LC50 (Table 1 results section) we 
noticed that the drug is able to enter into the cell nucleus within ten minutes after 
administration. After 24h, Dox is completely within the nucleus evidencing the inability of the 
cells to counteract its entrance and accumulation, at least at the concentrations used. The 
mechanism of Dox cytotoxicity is not completely understood although it appears to act 
principally through topoisomerase II inhibition [381]. Dox seems to stabilize catalytic 
intermediates of the enzyme onto target DNA thus it co-localise with chromatin [382]. After a 
48h treatment Dox is not uniformly distributed into the nuclei (as observed after 24h-
exposure) probably because the chromatin is starting to condensate and the apoptotic pathway 
has been already triggered as suggested previously [383]. However, form our results it seems 
that in the time-lapse between Dox entrance and apoptosis the cell is still able to modulate the 
mRNA and protein expression. We speculate that, in these way, the cell would be trying to 
limit Dox accumulation by increasing the ABC expression. Interestingly, even if  the ABCC1 
mRNA expression decreases in each cell line both at 24h and 48h, there is an increase in the 
protein expression in the tumoral cell lines compared to the immortalized hepatocytes (IHH). 
The differential behaviour between mRNA and protein expression suggest that the possible 
mechanism that determines the ABCC1 up-regulation is not the de-novo transcription but 
most probably something related to the protein turnover. 
ABCG2 seems to play a role only in less differentiated cells (JHH6) where, in spite of the 
decrease in the mRNA expression after 48h, the protein expression increases at 24h and 
remains higher than controls till 48h after (Results Fig. 5). ABCG2 seems not to be involved 
in cellular protection in HuH7 since there is a progressive protein down-regulation at 24h and 
48h (Results Fig. 4). Probably in these cells ABCG2 is not involved in anthracyclines 
detoxification, indeed untreated HuH7 cells express already high levels of ABCB1 and after 
Dox exposure the ABCB1 mRNA levels shows an subsequent additional increase after 24h, 
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and the protein after 48h suggesting a key role of this transporter in cellular protection. 
Another possible explanation about ABCG2 behaviour in these cells comes from Calcagno’s 
and coll. studies [384] where ABCG2 expression increased after long term Dox exposure of 
breast, ovarian and colon cancer cells (MCF-7, IGROV-1 and S-1), suggesting that longer 
exposure time is needed for observing variations in the expression of this transporter. Thus it 
might be possible that ABCG2 is involved in the drug long term response. However in our 
preliminary studies (data not shown) by exposing the IHH and JHH6 cells to low Dox doses 
for long time did not induce the ABCG2 up-regulation. Probably in hepatic derived cell lines 
ABCG2 has a secondary role in MDR, more important for these cells seem to be ABCC1 and 
ABCB1 whose participation in MDR in breast, ovarian and colon cancer cells was excluded 
by Calcagno and coll. [384].  
Preliminary data obtained by our group ( Rosso, N. et al. in preparation) suggest a more clear 
role of ABC transporters in determine cell survival by exposing the cells with Dox 
concentrations 1000 folds lower than the LC50. Such low drug doses, even if able to kill 
sensitive cells, induce a chemoresistance phenotype in surviving cells which overexpress 
these ABC transporters especially ABCB1 and ABCC1.  
The ability of Dox to induce ABCB1, ABCC1 and ABCG2 expression, even at low doses, 
should be taken into consideration in clinical practice. Dox is one of the widely used 
antineoplastic drugs and the understanding the role of Dox in the ABCB1, ABCC1 And 
ABCG2 induced chemoresistance would represent a useful point  for ameliorating current 
therapy in order to increase patients’ overall survival.  
During tumours treatment, if the first drug dose is not able to kill all the cancer cells, the 
surviving population undergoes to a selection process that makes those cells more resistant to 
drugs and at the same time they can recover cancer growth. Indeed Atalay and Coll. [385] 
found that an ABCB1 increased expression after anthracyclines treatment was associated with 
a decreased disease free and overall survival in patients with advanced breast cancer. These 
results suggest a possible role of ABC as negative prognostic markers in some type of cancers 
such as breast cancer pancreatic cancer [100,126,127] and HCC [132,133]. In particular, in 
liver tumours ABCC1 expression has been correlated with cancer stage and invasiveness 
[133]. 
In our cellular model we showed that Dox is able to modulate ABCB1, ABCC1 and ABCG2 
expression within 24h after the treatment suggesting that ABC up-regulation is an early event 
of cellular adaptation. Although cells are no more able to modulate gene expression, as 
demonstrated by a general mRNA down-regulation, they are probably able to decrease ABC 
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turnover determining the ABC protein up-regulation as observed in the tumoral cell lines 
(HuH7 and JHH6). We are not able to correlate the tumorigenic potential of the two tumoral 
cell lines with the ABC expression since the different behaviour of ABCs and the different 
contribution to MDR. Thus in order to better clarify the contribution of each single ABC to 
MDR our future steps will consider the use specific inhibitors such as: CP 100356 
Hydrochloride, Reversan and Ko134, specific ABCB1, ABCC1 and ABCG2 inhibitor 
respectively.  
Although not conclusive this study contributes in elucidating the role of Dox in modulating 
the pattern of expression of ABCB1, ABCC1 and ABCG2 in different HCC derived cell lines.  
By considering the contrasting and incomplete information available about the ABC 
transporters expression in HCC probably due to the different cellular in vitro models used, the 
different criteria of selection among studied patients and the difficulty to reproduce the 
clinical and patho-/physiological settings with an in vitro model, we are not able to strongly 
support our data with previously reported studies. However we provide more information 
about Dox influence on ABCB1, ACBC1 and ABCG2 expression in hepatic derived cell 
lines. The capability of Dox in modulating the ABCs that might induce a MDR phenotype 
states the limitations of chemotherapy in treating HCC and opens new research fields in 
alternative therapies.  
 
 
Task 2: Telomerase silencing effects in HCC  
The establishment of MDR limits the therapy options for HCC. Curative treatments, such as 
OLT or liver resection are not always immediately available and chemotherapy represents an 
alternative for the arrest of tumoral growth. Unfortunately the MDR phenomena could lead to 
unsuccessful drug treatments and other downstaging therapies are required. Gene silencing 
could represent, in a near future, a good option for HCC treatments since it is not subjected to 
MDR and to side effects that usually characterize chemotherapy.  
The best gene candidate for a successful gene therapy applied to cancer should be essential for 
cancer cell survival, growing and maintenance; over-expressed or exclusively expressed in 
tumoral cells and involved in as less pathways as possible. 
From literature four genes were selected: 1) Aurora kinase A; 2) midkine; 3) surviving; and 4) 
telomerase. Aurora Kinases are serine/threonine kinases that are essential for cell 
proliferation. They play a crucial role in cellular division by controlling chromatid 
segregation, in particular aurora kinase A has well-established but perhaps not yet fully 
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understood roles in centrosome function and duplication, mitotic entry, and bipolar spindle 
assembly. Aurora kinase A was found to be overexpressed in 61% HCC and its 
overexpression was associated with high-grade (grade II-IV), and high-stage (stage IIIB-IV) 
tumors, p53 mutation, infrequent -catenin mutation, and poor outcome [386]. Among our 
HCC samples, aurora kinase A results up-regulated in tumoral samples, although not 
significantly. Moreover it is moderately expressed also in controls. Midkine is an heparin-
binding growth and differentiation factor, it appears to enhance the angiogenic and 
proliferative activities of cancer cells. The expression of midkine (mRNA and protein 
expression) has been found to be elevated in multiple cancer types, whereas in normal adult 
tissues is low or undetectable [387-389]. In our case midkine is overexpressed in tumours and 
its expression decreases progressively from the tumoral to the distal portion of the HCC 
samples. Although expressed at very low levels midkine is also expressed in non tumoral 
samples. Surviving is a IAP (inhibitor of apoptosis) family member. It inhibits the caspase’s 
activation [390]. Its overexpression has an oncogenic potential because it may overcome the 
G2/M phase checkpoint to enforce progression of cells through mitosis, thus promoting 
proliferation. Survivin is highly expressed tumours, including HCC and is absent in normal 
cells [391]. There is no survivin differential expression between controls and tumoral samples 
analyzed in this study. The lack of a definite differential expression among tumoral, 
peripheral and distal portion of the diseased liver and the expression in controls, lead to 
discard of aurora kinase A, midkine and survivin as targets for gene therapy.  
On the contrary, telomerase reverse transcriptase is overexpressed in tumoral samples with a 
significant lower expression in peripheral (p<0.01) and distal (p<0.001) tissues. Moreover, as 
expected, no telomerase mRNA is detectable in non tumoral samples. For these reasons 
telomerase is eligible for the gene silencing experiments. hTERT is expressed in 100% of 
tumoral HCC tissues analysed and this is in accordance with previous studies which found 
telomerase to be expressed in 80-100% of HCCs [259,261]. Although the evidence that 
telomerase is expressed in HCC, very little information exist about the effects of its inhibition 
in this cancer type supporting our goal of silencing hTERT. 
RNA interference (RNAi) is a gene silencing process induced by 21–23-nucleotide RNA 
duplexes called small interfering RNAs (siRNAs) and resulting in sequence-specific 
messenger RNA degradation post-transcriptionally in the cellular cytoplasmic region. 
Among the different purposes for which the silencing techniques have been developed, more 
and more interest is given to the clinical applications. Recently several siRNAs for clinical 
use have been developed, most of them are in phase II clinical trial, such as Excellair, 
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targeting SYK kinase, used for asthma treatments and distributed by ZaBeCor; and QPI-1002, 
targeting p53, for acute renal failure and distributed by Quark/Novartis. 
Designing a siRNA for in vivo applications involves the use of several devices, for example 
the siRNA should be as much specific as possible to avoid off-target effects. Using the lowest 
effective concentration helps in preventing the off-target effects. The target secondary 
structure should also be taken into consideration since it can influence the siRNA efficacy 
[392]. Moreover the inflammatory response that could derive from the siRNA cellular uptake 
should be considered [393]. The induction of the proinflammatory cytokines by dsRNAs 
could lead to a cellular improper response. Kim and coll. [394] showed that direct dsRNA 
Dicer substrates can prevent inflammation. In our case the accurate design of a direct Dicer 
dsRNA against hTERT (SirTel 1) has been shown to successfully not induce the TNFα, IL6 
and IL8 expression (Fig. 11, results section). In contrast the “standard” 3’overhang dsRNA 
(SirTel 2, SirTel 3, SirTel 4) trigger an acute response from the innate immune system (Fig. 
11, results section). 
The silencing efficacy of each designed siRNA was tested in JHH6 cell line, which have the 
highest hTERT expression among the four cell lines evaluated (Fig. 10, results section). 
SirTel 1 and SirTel 4 are the most effective siRNAs in reducing hTERT expression in a dose 
dependent manner after 72h silencing (Fig. 12, results section). To assess the presence of off-
target effects, primary cultures of human fibroblasts were included into the experiments. 
Human fibroblasts are telomerase negative cells and for this reason they have a limited life 
span. These cells were transfected with SirTel 1 and SirTel 4 and cell viability was evaluated. 
In SirTel 1 transfected cells, the observed reduction in cell viability was due only to the 
vehicle. On the contrary the cellular decreased cell viability observed in SirTel 4 transfected 
cells is not only due to the use of the transfection reagent but also by the SirTel 4 uptake (Fig. 
13, results section). These results indicate that, in a telomerase negative setting, SirTel 4 
induces an unspecific cell toxicity probably due to off-target effects. 
The poor SirTel 2 and SirTel 3 silencing effect, the inflammatory response induced by SirTel 
2, SirTel 3 and SirTel 4, and the off-target effects caused by SirTel 4 lead to the election of 
the only SirTel 1 (the direct Dicer substrate) as siRNA candidate for further silencing 
experiments in JHH6 cells.  
Although there is a dose dependent hTERT silencing effect induced by SirTel 1, we decided 
to use for most of the experiments the lower effective dose (25nM), even if this concentration 
induce a 50% decrease in hTERT mRNA expression in spite of the marked silencing efficacy 
of higher SirTel 1 concentrations (100nM). Important to notice is that hTERT gene as the 
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other components of Telomerase holoenzyme naturally may be subjected to 
haploinsufficiency thus a 50% reduction in telomerase expression could be sufficient to obtain 
the desired effects.  
hTERT silencing has not only effect in the mRNA expression but also in the telomerase 
activity, validating the effectiveness of the silencing system. Indeed, after hTERT silencing 
there is more than 60% reduction (p<0.001) in the total product generated from active 
telomerase (Fig. 14, results section). 
Time course experiments (Fig. 15, results section) evidenced that hTERT reaches the lower 
mRNA expression at 72h of 25nM SirTel 1 silencing, thus at this time point we expect to 
observe the silencing effects in JHH6 cells. The first evident consequence of hTERT silencing 
is a morphological change of treated cells compared to controls. Only the siRNA transfected 
cells change their morphology from a fibroblast-like shape to an hepatocyte-like shape. The 
altered phenotype can be appreciated both by optical microscope and by flow cytometry 
analysis (Fig. 16 and 17, results section). These modifications that makes JHH6 more similar 
to normal hepatocytes lead us to the assessment of hepatic hallmarks in these cells. 
The albumin expression is a typical feature of normal hepatocytes, thus we decided to 
evaluate its expression in silenced cells. Albumin is not expressed or expressed at very low 
levels in poor differentiated untreated JHH6 cells but it becomes expressed after hTERT 
silencing. Although not significant, due to high S.Ds (to notice that in most samples albumin 
mRNA is detectable only after hTERT silencing), the maximum albumin mRNA expression 
corresponds to the minimum in hTERT mRNA expression. The link between hTERT 
inhibition and albumin expression/cellular differentiation is not known, as a consequence 
these interesting results are eligible for future investigations on the telomerase extratelomeric 
effects.  
Several reports [395-397] showed that a telomerase inhibition results in an impaired cell 
growth, dependent on telomere length, taking weeks or months to occur. However Cao Y. and 
Coll. [342] demonstrated that hTERT silencing in human breast cancer cells results in an 
impaired cell survival and proliferation independently of telomere length. Similar results were 
obtained by Li S. and Coll. [398] in colon cancer and melanoma cell lines and by Gandellini 
P. and Coll. [399] in prostate cancer cells. In agreemente with these previously published 
[342,399] studies we observed a statistically significant G1 cell cycle arrest of silenced cells 
compared to untreated controls (Fig. 20 and 21, results section). Furthermore after 72h of 
25nM siRNA treatment there is a 37% reduction in cell viability and about the 60% of 
surviving cells are arrested in G1 phase, as mentioned before. This data resulted more 
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interesting especially when compared with the percentage of viable cells after 72h of 25nM 
Dox treatment. 
Indeed Dox treatment determines only a 15% reduction in cell viability. Thus SirTel 1 
resulted more effective in reducing cell viability than Dox, especially at lower concentrations. 
This has important implications for a potential clinical use of this molecular strategy. The use 
of the siRNA instead of chemotherapeutic drugs could prevent all the side effects generally 
associated with chemotherapy.  
The rapid cell death and cell cycle arrest caused by hTERT depletion highlight the presence of 
a novel unknown pathway that links telomerase to cell survival independently of telomere 
length. This is supported by previous observations in which targeting hTERT or hTERC has 
similar effect in telomerase activity, but only the down-regulation of hTERT causes a rapid 
decline in cell growth suggesting an enzymatic activity independent mechanism by which 
hTERT maintains tumor cell survival and proliferation in human prostate cancer cells DU145 
[400].  
Other interesting results were obtained when, after an initial silencing, cells were re-exposed 
to 25nM of SirTel 1. Re-exposure of the cells to additional 25nM of siRNA induces a 
reduction of mRNA levels by 76% compared to the amount already present after the first 
treatment (Fig. 22, results section). Thus supposing a possible clinical application for SirTel 1, 
a re-treatment every 4-5 days could be useful in deplete cancer cell populations. 
 
In summary, hTERT silencing in JHH6 cells with a direct dicer substrate siRNA induces a 
decreased hTERT mRNA expression and a decreased telomerase activity. This leads to 
changes in cell morphology, from a fibroblast-like shape to an hepatocyte-like shape 
combined with an increased albumin expression; to a significant reduction in cell viability 
with more than 60% of surviving cells arrested in cell cycle phase. All together these results 
suggest a possible future application for telomerase silencing as anticancer treatment. 
In a clinical setting, telomerase inhibition may work as a down-staging therapy in conjunction 
with surgery or after an initial surgery, telomerase inhibition might be used in an adjuvant 
setting to limit the recovery of residual cancer cells. Moreover telomerase inhibition  might 
act in a synergistic fashion with existing therapeutic modalities and amplify their 
effectiveness.  
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